Blog

Autism Resources

by in Uncategorized April 9, 2014

 

In My Own Words

Phewwww!!  What you’ll find below is a compilation of everything that I have thus far…I think! Help me out, If you have autism resources that are not listed here and you would like to share, please feel free to email me.  I will look over them and if all checks out, I will post them here! Thank you in advance, and I appreciate you taking the time to sift through and educate yourself. 🙂

And a few more things…

  • Some of these studies listed are dated from years ago, I get it.  To some, they are “outdated.”  I don’t look at it this way… Yes, science is always evolving and new studies outdate the old ones.  My point by posting the older studies is this: no study should be taken as the “gold standard,” always question, always continue researching… and just because one study says the end outcome makes X, Y, Z valid or invalid, doesn’t mean that a study in the future won’t perhaps have a different outcome…  and just because a study might be dated 1976 doesn’t mean the study is outdated.
  • If you take a look at the Merck package insert for the 2014 MMRII, 90% of the studies cited are from the 1960’s, 70’s, and 80’s…
  • Yes, I have Dr. Andrew Wakefield’s studies cited also.  For more information as to why, please click here.
  • Also, most studies do not have links to them yet.  Please be patient, I will get to them as soon as possible!

“The important thing is not to stop questioning. Curiosity has its own reason for existing. One cannot help but be in awe when he contemplates the mysteries of eternity, of life, of the marvelous structure of reality. It is enough if one tries merely to comprehend a little of this mystery every day. Never lose a holy curiosity.”  

~Albert Einstein, US (German-born) physicist (1879 – 1955)

Autism Websites

Autism Books

Autism Articles

Autism and Lab Testing

Autism Studies

Autism the Epidemic

  • Arvidsson T, Danielsson B, Forsberg P, et al. Autism in 3-6-year-old children in a suburb of Goteborg, Sweden. Autism 1997;1:163–73.
  • Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, Charman T. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet. 2006 Jul 15;368(9531):210-5.
  • Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ. The incidence of autism in Olmsted County, Minnesota, 1976-1997: results from a population-based study. Arch Pediatr Adolesc Med. 2005 Jan;159(1):37-44.
  • Baron-Cohen S. The extreme male brain theory of autism. Trends Cogn Sci. 2002 Jun 1;6(6):248-254.
  • Baron-Cohen S. The hyper-systemizing, assortative mating theory of autism. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jul;30(5):865-72.
  • Bertrand J, Mars A, Boyle C, Bove F, Yeargin-Allsopp M, Decoufle P. Prevalence of Autism in a United States Population: The Brick Township, New Jersey, Investigation. Pediatrics. 2001;108;1155-1161.
  • Blaxill MF. Any changes in prevalence of autism must be determined. BMJ. 2002 Feb 2;324(7332):296.
  • Blaxill MF, Baskin DS, Spitzer WO. Blaxill, Baskin, and Spitzer on Croen et al. (2002), the changing prevalence of autism in California. J Autism Dev Disord. 2003 Apr;33(2):223-6; discussion 227-9.
  • Bryson SE, Clark BS, Smith IM. First report of a Canadian epidemiological study of autistic syndromes. J Child Psychiatry. 1988 Jul;29(4)433-45.
  • Burd L, Fisher W, Kerbeshian J. A prevalence study of pervasive developmental disorders in North Dakota. J Am Acad Child Adolesc Psychiatry. 1987 Sep;26(5):700-3.
  • Burd L, Kerbeshian J, Klug MG, McCulloch K. A prevalence methodology for mental illness and developmental disorders in rural and frontier settings. Int J Circumpolar Health. 2000 Jan;59(1):74-86.
  • Byrd, Robert. MIND Institute. Report to the Legislature on the Principle Findings from The Epidemiology of Autism in California: A Comprehensive Pilot Study. UC Davis 17 Oct 2002. www.dds.ca.gov/autism/pdf/study_final.pdf
  • California Department of Developmental Services “Changes in the Population of Persons with Autism and Pervasive Developmental Disorders in California’s Developmental Services System: 1987 through 1998.” Report to the Legislature March 1, 1999:1-19.
  • Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children: confirmation of high prevalence. Am J Psychiatry. 2005 Jun;162(6):1133-41.
  • Chang HL, Juang YY, Wang WT, Huang CI, Chen CY, Hwang YS. Screening for autism spectrum disorder in adult psychiatric outpatients in a clinic in Taiwan. Gen Hosp Psychiatry. 2003 Jul-Aug;25(4):284-8.
  • Charman T. The prevalence of autism spectrum disorders. Recent evidence and future challenges. Eur Child Adolesc Psychiatry. 2002 Dec;11(6):249-56.
  • Croen LA, Grether JK, Hoogstrate J, Selvin S. The changing prevalence of autism in California. J Autism Dev Disord. 2002 Jun;32(3):207-15.
  • Croen LA, Grether JK. A Response to Blaxill, Baskin, and Spitzer on Croen et al. (2002), “The Changing Prevalence of Autism in California.” J Autism Dev Disord, vol 33 April 2003, pp227-229(3).
  • Ganz, Michael. “The Costs of Autism.” Understanding Autism: From Basic Neuroscience to Treatment. Eds. Steven O. Moldin, John L R Rubenstein, CRC Press, 2006. 
  • Gillberg C, Cederlund M, Lamberg K, Zeijlon L. Brief Report: “The Autism Epidemic”. The registered prevalence of autism in a Swedish urban area. J Autism Dev Disord. 2006 Mar 28.
  • Gillberg C, Steffenburg S, Schaumann H. Is autism more common now than ten years ago? Br J Psychiatry. 1991 Mar;158:403-9.
  • Gillberg C, Wing L. Autism: not an extremely rare disorder. Acta Psychiatr Scand. 1999 Jun;99(6):399-406.
  • Harrington JW, Rosen L, Garnecho A, Patrick PA. Parental perceptions and use of complementary and alternative medicine practices for children with autistic spectrum disorders in private practice. J Dev Behav Pediatr. 2006 Apr;27(2 Suppl):S156-61.
  • Honda H, Shimizu Y, Imai M, Nitto Y. Cumulative incidence of childhood autism: a total population study of better accuracy and precision. Dev Med Child Neurol. 2005 Jan;47(1):10-8.
  • Hoshino Y, Kumashiro H, Yashima Y, Tachibana R, Watanabe M. The epidemiological study of autism in Fukushima-ken. Folia Psychiatr Neurol Jpn. 1982;36(2):115-24.
  • Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Association between thimerosal-containing vaccine and autism. JAMA. 2003 Oct;290(13):1763-6.
  • Icasiano F, Hewson P, Machet P, Cooper C, Marshall A. Childhood autism spectrum disorder in the Barwon region: a community based study. J Pediatr Child Health. 2004 Dec;40(12):696-701.
  • Kadesjo B, Gillberg C, Hagberg B. Brief report: autism and Asperger syndrome in seven-year-old children: a total population study. J Autism Dev Disord. 1999 Aug;29(4):327-31.
  • Kanner L. Autistic disturbances of affective contact. Acta Paedopsychiatr. 1968;35(4): 100-36.
  • Kielinen M, Linna SL, Moilanen I. Autism in Northern Finland. Eur Child Adolesc Psychiatry. 2000 Sep;9(3):162-7.
  • Kirby RS, Brewster MA, Canino CU, Pavin M. Early childhood surveillance of developmental disorders by a birth defects surveillance system: methods, prevalence comparisons, and mortality patterns. J Dev Behav Pediatr. 1995 Oct;16(5):318-26.
  • Lauritsen MB, Pedersen CB, Mortensen PB. The incidence and prevalence of pervasive developmental disorders: a Danish population-based study. Psychol Med. 2004 Oct;34(7):1339-46.
  • Madsen KM, Hviid A, Vestergaard M, Schendel D, Wohlfart J, Thorsen P, Olsen J, Melbye M. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med. 2002 Nov 7;347(19):1477-82.
  • Madsen KM, Lauritsen MB, Pedersen CB, Thorsen P, Plesner AM, Andersen PH, Mortensen PB. Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. Pediatrics. 2003 Sep;112(3 Pt 1):604-6.
  • Magnusson P, Saemundsen E. Prevalence of autism in Iceland. J Autism Dev Disord. 2001 Apr;31(2):153-63.
  • Nylander L, Gillberg C. Screening for autism spectrum disorders in adult psychiatric outpatients: a preliminary report. Acta Pxychiatr Scand. 2001 Jun;103(6):428-34.
  • Powell JE, Edwards A, Edwards M, Pandit BS, Sungum-Paliwal SR, Whitehouse W. Changes in the incidence of childhood autism and other autistic spectrum disorders in preschool children from two areas of the West Midlands, UK. Dev Med Child Neurol. 2000 Sep;42(9):624-8.
  • Rimland, Bernard. Infantile Autism: The Syndrome and Its Implications for a Neural Theory of Behavior. Prentice Hall: 1964.
  • Ritvo ER, Freeman BJ, Pingree C, Mason-Brothers A, Jorde L, Jenson WR, McMahon WM, Petersen PB, Mo A, Ritvo A. The UCLA-University of Utah epidemiologic survey of autism: prevalence. Am J Psychiatry. 1989 Feb;146(2)194-9.
  • Schattner A, Fletcher RH. Pearls and pitfalls in patient care: need to revive traditional clinical values. Am J Med Sci. 2004 Feb;327(2):79-85.
  • Scott FJ, Baron-Cohen S, Bolton P, Brayne C. Brief report: prevalence of autism spectrum conditions in children aged 5-11 years in Cambridgeshire, UK. Autism. 2002 Sep;6(3)231-7.
  • Smeeth L, Cook C, Fombonne PE, Heavey L, Rodrigues LC, Smith PG, Hall AJ. Rate of first recorded diagnosis of autism and other pervasive developmental disorders in a United Kingdom general practice 1988 to 2001. BMC Med. 2004 Nov 9;2:39.
  • Steffenberg S, Gillberg C. Autism and autistic-like conditions in Swedish rural and urban areas: a population study. Br J Psychiatry. 1986 Jul;149:81-7.
  • Sumi S, Taniai H, Miyachi T, Tanemura M. Sibling risk of pervasive developmental disorder estimated by means of an epidemiologic survey in Nagoya, Japan. J Hum Genet. 2006 Mar 25.
  • Szatmari P. Thinking about Autism, Asperger Syndrome and PDDNOS. PRISME, 34:24-34, 2001.Wing L, Potter D. The epidemiology of autistic spectrum disorders: Is the prevalence rising? Ment Retard Dev Disabil Res Rev. 2002;8(3):151-61.
  • Volkmar F, Bregman J, Cohen D, Cicchetti D. DSM-III and DSM-III-R Diagnoses of Autism. Am J Psychiatry. 1988 Nov 145:11;1404-1408.
  • Yazbak FE. Autism in the United States: a perspective. JPANDS. 2003 8:4:103-107.
  • Yeargin-Allsopp M, Rice C, Karapurker T, Doernberg N, Boyle C, Murphy C. Prevalence of autism in a US metropolitan area. JAMA. 2003 Jan 1;289(1)49-55.

Back to Top

Dr. Martha Herbert, MD, PhD – Neurology (Harvard)

Back to Top

Autism and the Brain/Neurological System

  • rat serotonin study
  • prefrontal cortex and autism
  • Epileptiform Activity and Autism
  • Endophenotype and Related Genotypes Autism
  • cholinergic activity autism pdf
  • Neuro Activation and Inflammation Vargas
  • cerebral cortex
  • Acosta MT, Pearl PL. Imaging data in autism: from structure to malfunction. Semin Pediatr Neurol. 2004 Sep;11(3):205-13.
  • Akshoomoff N, Pierce K, Courchesne E. The neurobiological basis of autism from a developmental perspective. Dev Psychopathol. 2002 Summer;14(3):613-34.
  • Ashwood P, Wills S, Van de Water J. The immune response in autism: a new frontier for autism research. J Leukoc Biol. 2006 Jul;80(1):1-15.
  • Axelrod FB, Chelimsky GG, Weese-Mayer DE. Pediatric autonomic disorders. Pediatrics. 2006 Jul;118(1):309-21.
  • Bittigau P, Ikonomidou C. Glutamate in neurologic diseases. J Child Neurol. 1997 Nov;12(8):471-85.
  • Bradl M, Hohlfeld R. Molecular pathogenesis of neuroinflammation. J Neurol Neurosurg Psychiatry. 2003 Oct;74(10):1364-70.
  • Chugani DC, Muzik O, Rothermel R, Behen M, Chakraborty P, Mangner T, da Silva EA, Chugani HT. Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys. Ann Neurol. 1997 Oct;42(4):666-9.
  • Conroy J, Meally E, Kearney G, Fitzgerald M, Gill M, Gallagher L. Serotonin transporter gene and autism: a haplotype analysis in an Irish autistic population. Mol Psychiatry. 2004 Jun;9(6):587-93.
  • Cook EH. Autism: review of neurochemical investigation. Synapse. 1990;6(3):292-308.
  • Cook EH Jr, Perry BD, Dawson G, Wainwright MS, Leventhal BL. Receptor inhibition by immunoglobulins: specific inhibition by autistic children, their relatives, and control subjects. J Autism Dev Disord. 1993 Mar;23(1):67-78.
  • Coutinho AM, Oliveira G, Morgadinho T, Fesel C, Macedo TR, Bento C, Marques C, Ataide A, Miguel T, Borges L, Vicente AM. Variants of the serotonin transporter gene (SLC6A4) significantly contribute to hyperserotonemia in autism. Mol Psychiatry. 2004 Mar;9(3):264-71.
  • Courchesne E, Karns CM, Davis HR, Ziccardi R, Carper RA, Tigue ZD, Chisum HJ, Moses P, PierceK, Lord C, Lincoln AJ, Pizzo S, Schreibman L, Haas RH, Akshoomoff NA, Courchesne RY. Unusual brain growth patterns in early life in patients with autistic disorder: an MRI study. Neurology. 2001 Jul 24;57(2):245-54.
  • Courchesne E, Townsend J, Akshoomoff NA, Saitoh O, Yeung-Courchesne R, Lincoln AJ, James HE, Haas RH, Schreibman L, Lau L. Impairment in shifting attention in autistic and cerebellar patients. Behav Neurosci. 1994 Oct;108(5):848-65.
  • Courchesne E, Pierce K. Brain overgrowth in autism during a critical time in development: implications for frontal pyramidal neuron and interneuron development and connectivity. Int J Dev Neurosci. 2005 Apr-May;23(2-3):153-70.
  • Courchesne E, Townsend J, Saitoh O. The brain in infantile autism: posterior fossa structures are abnormal. Neurology. 1994 Feb;44(2):214-23.
  • Courchesne E. Neuroanatomic imaging in autism. Pediatrics. 1991 May;87(5 Pt 2):781-90.
  • Croonenberghs J, Fegert JM, Findling RL, De Smedt G, Van Dongen S; Risperidone Disruptive Behavior Study Group. Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry. 2005 Jan;44(1):64-72.
  • Dunzendorfer S, Kaser A, Meierhofer C, Tilg H, Wiedermann CJ. Cutting edge: peripheral neuropeptides attract immature and arrest mature blood-derived dendritic cells. J Immunol. 2001 Feb 15;166(4):2167-72.
  • Fatemi SH, Halt AR, Stary JM, Kanodia R, Schulz SC, Realmuto GR. Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. Biol Psychiatry. 2002 Oct 15;52(8):805-10.
  • Findling RL, Aman MG, Eerdekens M, Derivan A, Lyons B. Risperidone Disruptive Behavior Study Group. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry. 2004 Apr;161(4):677-84.
  • Fukuda T, Sugie H, Ito M, Sugie Y. Clinical evaluation of treatment with fluvoxamine, a selective serotonin reuptake inhibitor in children with autistic disorder. No To Hattatsu. 2001 Jul;33(4):314-8.
  • Gershon, Michael. The Second Brain: A Groundbreaking New Understanding of Nervous Disorders of the Stomach and Intestine. Harper paperbacks, 1999. P. xii.
  • Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001 Apr;81(2):629-83.
  • Green L, Fein D, Modahl C, Feinstein C, Waterhouse L, Morris M. Oxytocin and autistic disorder: alterations in peptide forms. Biol Psychiatry. 2001 Oct 15;50(8):609-13.
  • Hazlett HC, Poe MD, Gerig G, Smith RG, Piven J. Cortical gray and white brain tissue volume in adolescents and adults with autism. Biol Psychiatry. 2006 Jan 1;59(1):1-6.
  • Ishizaki A, Sugama M, Takeuchi N. Usefulness of melatonin for developmental sleep and emotional/behavior disorders—studies of melatonin trial on 50 patients with developmental disorders. No To Hattatsu. 1999 Sep;31(5):428-37.
  • Jan JE, O’Donnell ME. Use of melatonin in the treatment of paediatric sleep disorders. J Pineal Res. 1996 Nov;21(4):193-9.
  • Jarskog LF, Xiao H, Wilkie MB, Lauder JM, Gilmore JH. Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro. Int J Dev Neurosci. 1997 Oct;15(6):711-6.
  • Kawasaki Y, Yokota K, Shinomiya M, Shimizu Y, Niwa S. Brief report: electroencephalographic paroxysmal activities in the frontal area emerged in middle childhood and during adolescence in a follow-up study of autism. J Autism Dev Disord. 1997 Oct;27(5):605-20.
  • Kern JK, Jones AM. Evidence of toxicity, oxidative stress, and neuronal insult in autism. J Toxicol Environ Health B Crit Rev. 2006 Nov-Dec;9(6):485-99.
  • Knivsberg AM, Reichelt KL, Nodland M. Reports on dietary intervention in autistic disorders. Nutr Neurosci. 2001;4(1):25-37.
  • Lam KS, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil. 2006 May-Jun;27(3):254-89.
  • Larson SJ. Behavioral and motivational effects of immune-system activation. J Gen Psychol. 2002 Oct;129(4):401-14.
  • Lee M, Martin-Ruiz C, Graham A, Court J, Jaros E, Perry R, Iversen P, Bauman M, Perry E. Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain. 2002 Jul;125(Pt 7):1483-95.
  • Malow BA. Sleep disorders, epilepsy, and autism. Ment Retard Dev Disabil Res Rev. 2004;10(2):122-5.
  • Martineau J, Barthelemy C, Jouve J, Muh JP, Lelord G. Monoamines (serotonin and catecholamines) and their derivatives in infantile autism: age-related changes and drug effects. Dev Med Child Neurol. 1992 Jul;34(7):593-603.
  • McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry. 1996 Nov;53(11):1001-8.
  • Mignini F, Streccioni V, Amenta F. Autonomic innervation of immune organs and neuroimmune modulation. Auton Autacoid Pharmacol. 2003 Feb;23(1):1-25.
  • Modahl C, Green L, Fein D, Morris M, Waterhouse L, Feinstein C, Levin H. Plasma oxytocin levels in autistic children. Biol Psychiatry. 1998 Feb 15;43(4):270-7.
  • Narayan M, Srinath S, Anderson GM, Meundi DB. Cerebrospinal fluid levels of homovanillic acid and 5-hydroxyindoleacetic acid in autism. Biol Psychiatry. 1993 Apr 15-May 1;33(8-9):630-5.
  • Nelson KB, Grether JK, Croen LA, Dambrosia JM, Dickens BF, Jelliffe LL, Hansen RL, Phillips TM. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol. 2001 May;49(5):597-606.
  • Palmen SJ, van Engeland H, Hof PR, Schmitz C. Neuropathological findings in autism. Brain. 2004 Dec;127(Pt 12):2572-83.
  • Pandina GJ, Aman MG, Findling RL. Risperidone in the management of disruptive behavior disorders. J Child Adolesc Psychopharmacol. 2006 Aug;16(4):379-92.
  • Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F. Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial. J Autism Dev Disord. 2006 Oct 4.
  • Pashenkov M, Teleshova N, Link H. Inflammation in the central nervous system: the role for dendritic cells. Brain Pathol. 2003 Jan;13(1):23-33.
  • Peterson PK, Molitor TW, Chao CC. The opioid-cytokine connection. J Neuroimmunol. 1998 Mar 15;83(1-2):63-9.
  • Piven J, Arndt S, Bailey J, Andreasen N. Regional brain enlargement in autism: a magnetic resonance imaging study. J Am Acad Child Adolesc Psychiatry. 1996 Apr;35(4):530-6.
  • Redcay E, Courchesne E. When is the brain enlarged in autism? A meta-analysis of all brain size reports. Biol Psychiatry. 2005 Jul 1;58(1):1-9.
  • Reichelt KL, Knivsberg AM. Can the pathophysiology of autism be explained by the nature of the discovered urine peptides? Nutr Neurosci. 2003 Feb;6(1):19-28.
  • Shattock P, Kennedy A, Rowell F, Berney T. Role of neuropeptides in autism and their relationship with classical neurotransmitters.?Brain Dysfunction 1990:3: 328-345.
  • Shattock P, Lowdon G. Proteins, peptides and autism: Part 2: Implications for the education and care of people with autism. Brain Dysfunction. 1991;4:323-334.
  • Symons FJ, Thompson A, Rodriguez MC. Self-injurious behavior and the efficacy of naltrexone treatment: a quantitative synthesis. Ment Retard Dev Disabil Res Rev. 2004;10(3):193-200.
  • Todd RD, Ciaranello RD. Demonstration of inter- and intraspecies differences in serotonin binding sites by antibodies from an autistic child. Proc Natl Acad Sci U S A. 1985 Jan;82(2):612-6.
  • Trevathan E. Seizures and epilepsy among children with language regression and autistic spectrum disorders. J Child Neurol. 2004 Aug;19 Suppl 1:S49-57.
  • Trottier G, Srivastava L, Walker CD. Etiology of infantile autism: a review of recent advances in genetic and neurobiological research. J Psychiatry Neurosci. 1999 Mar;24(2):103-15.
  • Tuchman R, Rapin I. Epilepsy in autism. Lancet Neurol. 2002 Oct;1(6):352-8.
  • Tuchman R. Autism and Epilepsy: What Has Regression got to do with it? Epilepsy Currents. 6(4) 2006:107-111.
  • Tuchman RF. Language disorders: is EEG clinically useful? Rev Neurol. 1997 May;25(141):744-9.Ballaban-Gil K, Tuchman R. Epilepsy and epileptiform EEG: association with autism and language disorders. Ment Retard Dev Disabil Res Rev. 2000;6(4):300-8.
  • Turgay A, Binder C, Snyder R, Fisman S. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics. 2002 Sep;110(3):e34.
  • Vega JA, Garcia-Suarez O, Hannestad J, Perez-Perez M, Germana A. Neurotrophins and the immune system. J Anat. 2003 Jul;203(1):1-19.
  • Wilson CJ, Finch CE, Cohen HJ. Cytokines and cognition—the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc. 2002 Dec;50(12):2041-56.
  • Young LJ, Pitkow LJ, Ferguson JN. Neuropeptides and social behavior: animal models relevant to autism. Mol Psychiatry. 2002;7 Suppl 2:S38-9.
  • Zagon IS, McLaughlin PJ. Identification of opioid peptides regulating proliferation of neurons and glia in the developing nervous system. Brain Res. 1991 Mar 1;542(2):318-23.
  • Zhao B, Schwartz JP. Involvement of cytokines in normal CNS development and neurological diseases: recent progress and perspectives. J Neurosci Res. 1998 Apr 1;52(1):7-16.
  • Zilbovicius M, Garreau B, Samson Y, Remy P, Barthelemy C, Syrota A, Lelord G. Delayed maturation of the frontal cortex in childhood autism. Am J Psychiatry. 1995 Feb;152(2):248-52.

Back to Top

Autism and Genetics

  • molecular analysis CNTNAP2
  • MECP2 promoter methylation and X chromosome
  • Fragile X protein in translation
  • CNTNAP2 and familial risk
  • CNTNAP UCLA study
  • Autism and chromosome 15
  • ASD and protein L10
  • Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E, Rutter M. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med. 1995 Jan;25(1):63-77.
  • Bailey A, Palferman S, Heavey L, Le Couteur A. Autism: the phenotype in relatives. J Autism Dev Disord. 1998 Oct;28(5):369-92.
  • Bartak L, Rutter M, Cox A. A comparative study of infantile autism and specific development receptive language disorder. I. The children. Br J Psychiatry. 1975 Feb;126:127-45.
  • Campbell DB, Sutcliffe JS, Ebert PJ, Militerni R, Bravaccio C, Trillo S, Elia M, Schneider C, Melmed R, Sacco R, Persico AM, Levitt P. A genetic variant that disrupts MET transcription is associated with autism. Proc Natl Acad Sci U S A. 2006 Oct 19.
  • Comi AM, Zimmerman AW, Frye VH, Law PA, Peeden JN. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Child Neurol. 1999 Jun;14(6):388-94.
  • Cook EH. Genetics of autism. Ment Retard Dev Disabil Res Rev. 1998 4:113-120.
  • Cook EH Jr. Genetics of autism. Child Adolesc Psychiatr Clin N Am. 2001 Apr;10(2):333-50.
  • Croen LA, Grether JK, Yoshida CK, Odouli R, Van de Water J. Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. Arch Pediatr Adolesc Med. 2005 Feb;159(2):151-7.
  • Folstein S, Rutter M. Genetic influences and infantile autism. Nature 265, 726-728(24 Feb 1977.
  • Jorde LB, Hasstedt SJ, Ritvo ER, Mason-Brothers A, Freeman BJ, Pingree C, McMahon WM, Petersen B, Jenson WR, Mo A. Complex segregation analysis of autism. Am J Hum Genet. 1991 Nov;49(5):932-8.
  • Konstantareas MM, Homatidis S., Chromosomal abnormalities in a series of children with autistic disorder. J Autism Dev Disord. 1999 Aug;29(4):275-85.
  • Korvatska E, Van de Water J, Anders TF, Gershwin ME. Genetic and immunologic considerations in autism. Neurobiol Dis. 2002 Mar;9(2):107-25.
  • Le Couteur A, Bailey A, Goode S, Pickles A, Robertson S, Gottesman I, Rutter M. A broader phenotype of autism: the clinical spectrum in twins. J Child Psychol Psychiatry. 1996 Oct;37(7):785-801.
  • Lotter V.; Epidemiology of autistic conditions in young children. I. Prevalence. Soc. Psychiatry 1966, 1; 124-137.
  • Micali N, Chakrabarti S, Fombonne E., The broad autism phenotype: findings from an epidemiological survey. Autism. 2004 Mar;8(1):21-37.
  • Molloy CA, Morrow AL, Meinzen-Derr J, Dawson G, Bernier R, Dunn M, Hyman SL, McMahon WM, Goudie-Nice J, Hepburn S, Minshew N, Rogers S, Sigman M, Spence MA, Tager-Flusberg H, Volkmar FR, Lord C. Familial autoimmune thyroid disease as a risk factor for regression in children with Autism Spectrum Disorder: a CPEA Study. J Autism Dev Disord. 2006 Apr;36(3):317-24.
  • Nelson KB, Grether JK, Croen LA, Dambrosia JM, Dickens BF, Jelliffe LL, Hansen RL, Phillips TM. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol. 2001 May;49(5):597-606.
  • Risch N, Spiker D, Lotspeich L, Nouri N, Hinds D, Hallmayer J, Kalaydjieva L, McCague P, Dimiceli S, Pitts T, Nguyen L, Yang J, Harper C, Thorpe D, Vermeer S, Young H, Hebert J, Lin A, Ferguson J, Chiotti C, Wiese-Slater S, Rogers T, Salmon B, Nicholas P, Petersen PB, Pingree C, McMahon W, Wong DL, Cavalli-Sforza LL, Kraemer HC, Myers RM. A genomic screen of autism: evidence for a multilocus etiology. Am J Hum Genet. 1999 Aug;65(2):493-507.
  • Ritvo ER, Freeman BJ, Mason-Brothers A, Mo A, Ritvo AM. Concordance for the syndrome of autism in 40 pairs of afflicted twins. Am J Psychiatry.1985 Jan;142(1):74-7.
  • Smalley SL. Genetic influences in childhood-onset psychiatric disorders: autism and attention-deficit/hyperactivity disorder. Am J Hum Genet. 1997 Jun;60(6):1276-82.
  • Spiker D, Lotspeich L, Kraemer HC, Hallmayer J, McMahon W, Petersen PB, Nicholas P, Pingree C, Wiese-Slater S, Chiotti C, et al. Genetics of autism: characteristics of affected and unaffected children from 37 multiplex families. Am J Med Genet. 1994 Mar 15;54(1):27-35.
  • Steffenburg S, Gillberg C, Hellgren L, Andersson L, Gillberg IC, Jakobsson G. A twin study of autism in Denmark, Finland, Iceland, Norway and Sweden. J Child Psychol Psychiatry. 1989 May;30(3):405-16.
  • Sweeten TL, Bowyer SL, Posey DJ, Halberstadt GM, McDougle CJ. Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics. 2003 Nov;112(5):e420.
  • Szatmari P. Heterogeneity and the genetics of autism. J Psychiatry Neurosci. 1999 Mar;24(2):159-65.
  • Trottier G, Srivastava, Walker CD. Etiology of infantile autism: a review of recent advances and neurobiological research. J Psychiatry neurosci. 1999Mar;24(2):103-115.

Back to Top

Autism and Immunological System

  • Ahlsen G, Rosengren L, Belfrage M, Palm A, Haglid K, Hamberger A, Gillberg C. Glial fibrillary acidic protein in the cerebrospinal fluid of children with autism and other neuropsychiatric disorders. Biol Psychiatry. 1993 May 15;33(10):734-43.
  • Ashwood P, Anthony A, Pellicer AA, Torrente F, Walker-Smith JA, Wakefield AJ. Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology. J Clin Immunol. 2003 Nov;23(6):504-17.
  • Ashwood P, Anthony A, Torrente F, Wakefield AJ. Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms: mucosal immune activation and reduced counter regulatory interleukin-10. J Clin Immunol. 2004 Nov;24(6):664-73.
  • Ashwood P, Van de Water J. Is autism an autoimmune disease? Autoimmun Rev. 2004 Nov;3(7-8):557-62.
  • Ashwood P, Willis S, Van de Water J. The immune response in autism: a new frontier for autism research. J Leuk Biol. 2006 Jul:80;1-15.
  • Bach JF. Infections and autoimmune diseases. J Autoimmun. 2005;25 Suppl:74-80.
  • Campbell DB, Sutcliffe JS, Ebert PJ, Militerni R, Bravaccio C, Trillo S, Elia M, Schneider C, Melmed R, Sacco R, Persico AM, Levitt P. A genetic variant that disrupts MET transcription is associated with autism. Proc Natl Acad Sci U S A. 2006 Oct 19.
  • Chess S, Fernandez P, Korn S. Behavioral consequences of congenital rubella. J Pediatr. 1978 Oct;93(4):699-703.
  • Comi AM, Zimmerman AW, Frye VH, Law PA, Peeden JN. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Child Neurol. 1999 Jun;14(6):388-94. Nov;112(5):e420.
  • Connolly AM, Chez MG, Pestronk A, Arnold ST, Mehta S, Deuel RK. Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. J Pediatr. 1999 May;134(5):607-13.
  • Croen LA, Najjar DV, Ray GT, Lotspeich L, Bernal P. A comparison of health care utilization and costs of children with and without autism spectrum disorders in a large group-model health plan. Pediatrics. 2006 Oct;118(4):e1203-11.
  • Croonenberghs J, Wauters A, Devreese K, Verkerk R, Scharpe S, Bosmans E, Egyed B, Deboutte D, Maes M. Increased serum albumin, gamma globulin, immunoglobulin IgG, and IgG2 and IgG4 in autism. Psychol Med. 2002 Nov;32(8):1457-63.
  • Dalton P, Deacon R, Blamire A, Pike M, McKinlay I, Stein J, Styles P, Vincent A. Maternal neuronal antibodies associated with autism and a language disorder. Ann Neurol. 2003 Apr;53(4):533-7.
  • DeLong GR, Bean SC, Brown FR 3rd. Acquired reversible autistic syndrome in acute encephalopathic illness in children. Arch Neurol. 1981 Mar;38(3):191-4.
  • Denney DR, Frei BW, Gaffney GR. Lymphocyte subsets and interleukin-2 receptors in autistic children. J Autism Dev Disord. 1996 Feb;26(1):87-97.
  • Engstrom HA, Ohlson S, Stubbs EG, Maciulis A, Caldwell V, Odell JD, Torres A.R. Decreased Expression of CD95 (FAS/APO-1) on CD4+ T-lymphocytes from Participants with Autism. J Dev Phys Disabil. 2003 Jun 15;2:155-163(9).
  • Fallon J. Could one of the most widely prescribed antibiotics amoxicillin/ clavulanate “augmentin” be a risk factor for autism? Med Hypotheses. 2005;64(2):312-5.
  • Ferrante P, Saresella M, Guerini FR, Marzorati M, Musetti MC, Cazzullo AG. Significant association of HLA A2-DR11 with CD4 naive decrease in autistic children. Biomed Pharmacother. 2003 Oct;57(8):372-4.
  • Fiumara A, Sciotto A, Barone R, D’Asero G, Munda S, Parano E, Pavone L. Peripheral lymphocyte subsets and other immune aspects in Rett syndrome. Pediatr Neurol. 1999 Sep;21(3):619-21.
  • Furlano RI, Anthony A, Day R, Brown A, McGavery L, Thomson MA, Davies SE, Berelowitz M, Forbes van Gent T, Heijnen CJ, Treffers PD. Autism and the immune system. J Child Psychol Psychiatry. 1997 Mar;38(3):337-49.
  • Gupta S, Aggarwal S, Rashanravan B, Lee T. Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism. J Neuroimmunol. 1998 May 1;85(1):106-9.
  • Gurney JG, McPheeters ML, Davis MM. Parental report of health conditions and health care use among children with and without autism: National Survey of Children’s Health. Arch Pediatr Adolesc Med. 2006 Aug;160(8):825-30.
  • James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, Neubrander JA. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004 Dec;80(6):1611-7.
  • Jyonouchi H, Geng L, Ruby A, Reddy C, Zimmerman-Bier B. Evaluation of an association between gastrointestinal symptoms and cytokine production against common dietary proteins in children with autism spectrum disorders. J Pediatr. 2005 May;146(5):605-10.
  • Jyonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol. 2001 Nov 1;120(1-2):170-9.
  • Jyonouchi H, Sun S, Itokazu N. Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology. 2002;46(2):76-84.
  • Jyonouchi H, Geng L, Ruby A, Zimmerman-Bier B. Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention. Neuropsychobiology. 2005;51(2):77-85.
  • Konstantareas MM, Homatidis S. Ear infections in autistic and normal children. J Autism Dev Disord. 1987 Dec;17(4):585-94.
  • Korvatska E, Van de Water J, Anders TF, Gershwin ME. Genetic and immunologic considerations in autism. Neurobiol Dis. 2002 Mar;9(2):107-25.
  • Krause I, He XS, Gershwin ME, Shoenfeld Y. Brief report: immune factors in autism: a critical review. J Autism Dev Disord. 2002 Aug;32(4):337-45.
  • Libbey JE, Sweeten TL, McMahon WM, Fujinami RS. Autistic disorder and viral infections. J Neurovirol. 2005 Feb;11(1):1-10.
  • Lopez-Pison J, Rubio-Rubio R, Urena-Hornos T, Omenaca-Teres M, Sans A, Cabrerizo de Diago R, Pena-Segura JL. Retrospective diagnosis of congenital infection by cytomegalovirus in the case of one infant. Rev Neurol. 2005 Jun 16-30;40(12):733-6.
  • Lucarelli S, Frediani T, Zingoni AM, Ferruzzi F, Giardini O, Quintieri F, Barbato M, D’Eufemia P, Cardi E. Food allergy and infantile autism. Panminerva Med. 1995 Sep;37(3):137-41.
  • Mehler MF, Kessler JA. Cytokines in brain development and function. Adv Protein Chem. 1998;52:223-51.
  • Meyer U, Nyffeler M, Engler A, Urwyler A, Schedlowski M, Knuesel I, Yee BK, Feldon J. The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. J Neurosci. 2006 May 3;26(18):4752-62.
  • Molloy C, Morrow A, Meinzen-Derr J, Schleifer K, Dienger K, Manning-Courtney P, Altaye M, Wills-Karp M. Elevated cytokine levels in children with autism spectrum disorder. J Neuroimmunology. 2006;172:198-205.
  • Murch SH, Walker-Smith JA. Nutrition in inflammatory bowel disease. Baillieres Clin Gastroenterol. 1998 Dec;12(4):719-38.
  • Niehus R, Lord C. Early medical history of children with autism spectrum disorders. J Dev Behav Pediatr. 2006 Apr;27(2 Suppl):S120-7.
  • Okada K, Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya KJ, Sekine Y, Suda S, Suzuki K, Sugihara GI, Matsuzaki H, Sugiyama T, Kawai M, Minabe Y Takei N, Mori N. Decreased serum levels of transforming growth factor-beta1 in patients with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Oct 5.
  • Pardo CA, Vargas DL, Zimmerman AW. Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry. 2005 Dec;17(6):485-95.
  • Pletnikov MV, Jones ML, Rubin SA, Moran TH, Carbone KM. Rat model of autism spectrum disorders. Genetic background effects on Borna disease virus-induced developmental brain damage. Ann N Y Acad Sci. 2001 Jun;939:318-9.
  • Plioplys AV. Autism: electroencephalogram abnormalities and clinical improvement with valproic acid. Arch Pediatr Adolesc Med. 1994 Feb;148(2):220-2.
  • Plioplys AV, Greaves A. Yoshida W. Anti-CNS antibodies in childhood neurologic diseases. Neuropediatrics. 1989;20:93.
  • Rumsey JM, Ernst M. Functional neuroimaging of autistic disorders. Ment Retard Dev Disabil Res Rev. 2000;6(3):171-9.
  • Silva SC, Correia C, Fesel C, Barreto M, Coutinho AM, Marques C, Miguel TS, Ataide A, Bento C, Borges L, Oliveira G, Vicente AM. Autoantibody repertoires to brain tissue in autism nuclear families. J Neuroimmunol. 2004 Jul;152(1-2):176-82.
  • Singer HS, Morris CM, Williams PN, Yoon DY, Hong JJ, Zimmerman AW. Antibrain antibodies in children with autism and their unaffected siblings. J Neuroimmunol. 2006 Sep;178(1-2):149-155.
  • Singh VK. Plasma increase of interleukin-12 and interferon-gamma. Pathological significance in autism. J Neuroimmunol. 1996 May;66(1-2):143-5.
  • Singh VK. Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism. J Neuroimmunol. 1998 May 1;85(1):106-9.
  • Singh VK, Warren R, Averett R, Ghaziuddin M. Circulating autoantibodies to neuronal and glial filament proteins in autism. Pediatr Neurol. 1997 Jul;17(1):88-90.
  • Singh VK, Warren RP, Odell JD, Warren WL, Cole P. Antibodies to myelin basic protein in children with autistic behavior. Brain Behav Immun. 1993 Mar;7(1):97-103.
  • Singh VK, Singh EA, Warren RP. Hyperserotoninemia and serotonin receptor antibodies in children with autism but not mental retardation. Biol Psychiatry. 1997 Mar 15;41(6):753-5.
  • Singh VK, Rivas WH. Prevalence of serum antibodies to caudate nucleus in autistic children. Neurosci Lett. 2004 Jan 23;355(1-2):53-6.
  • Stubbs EG, Crawford ML. Depressed lymphocyte responsiveness in autistic children. J Autism Child Schizophr. 1977 Mar;7(1):49-55.
  • Sweeten TL, Bowyer SL, Posey DJ, Halberstadt GM, McDougle CJ. Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics. 2003 Sweeten TL, Posey DJ, McDougle CJ. High blood monocyte counts and neopterin levels in children with autistic disorder. Am J Psychiatry. 2003 Sep;160(9):1691-3.
  • Sweeten TL, Posey DJ, McDougle CJ. Brief report: autistic disorder in three children with cytomegalovirus infection. J Autism Dev Disord. 2004 Oct;34(5):583-6.
  • Sweeten TL, Posey DJ, Shankar S, McDougle CJ. High nitric oxide production in autistic disorder: a possible role for interferon-gamma. Bio Psychiatry. 2004 Feb 15:55(4):434-7.
  • Swisher CN, Swisher L. Letter: Congenital rubella and autistic behavior. N Engl J Med. 1975 Jul 24;293(4):198.
  • Todd RD, Hickok JM, Anderson GM, Cohen DJ. Antibrain antibodies in infantile autism. Biol Psychiatry. 1988 Mar 15;23(6):644-7.
  • Torrente F, Ashwood P, Day R, Machado N, Furlano RI, Anthony A, Davies SE, Wakefield AJ, Thomson MA, Walker-Smith JA, Murch SH. Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Mol Psychiatry. 2002;7(4):375-82, 334.
  • Trajkovski V, Ajdinski L, Spiroski M. Plasma concentration of immunoglobulin classes and subclasses in children with autism in the Republic of Macedonia: retrospective study. Croat Med J. 2004 Dec;45(6):746-9.
  • Tuchman RF, Rapin I, Shinnar S. Autistic and dysphasic children. I: Clinical characteristics. Pediatrics. 1991 Dec;88(6):1211-8.
  • Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005 Jan;57(1)67-81.
  • Vojdani A, Campbell AW, Anyanwu E, Kashanian A, Bock K, Vojdani E. Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J Neuroimmunol. 2002 Aug;129(1-2):168-77.
  • Wakefield AJ, Walker-Smith JA, Murch SH. Colonic CD8 and gamma delta T-cell infiltration with epithelial damage in children with autism. Pediatrics 2001;138:366-72.
  • Warren RP, Margaretten NC, Pace NC, Foster A. Immune abnormalities in patients with autism. J Autism Dev Disord. 1986 Jun;16(2):189-97.
  • Warren RP, Cole P, Odell JD, Pingree CB, Warren WL, White E, Yonk J, Singh VK. Detection of maternal antibodies in infantile autism. J Am Acad Child Adolesc Psychiatry. 1990 Nov;29(6):873-7.
  • Warren RP, Foster A, Margaretten NC. Reduced natural killer cell activity in autism. J Am Acad Child Adolesc Psychiatry. 1987 May;26(3):333-5.
  • Warren RP, Singh VK, Averett RE, Odell JD, Maciulis A, Burger RA, Daniels WW, Warren WL. Immunogenetic studies in autism and related disorders. Mol Chem Neuropathol. 1996 May-Aug;28(1-3):77-81.
  • Yonk LJ, Warren RP, Burger RA, Cole P, Odell JD, Warren WL, White E, Singh VK. CD4+ helper T cell depression in autism. Immunol Lett. 1990 Sep;25(4):341-5.
  • Zimmerman AW, Connors SL, Matteson KJ, Lee LC, Singer HS, Castaneda JA, Pearce DA. Maternal antibrain antibodies in autism. Brain Behav Immun. 2006 Oct 5.
  • Zimmerman AW, Jyonouchi H, Comi AM, Connors SL, Milstien S, Varsou A, Heyes MP. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol. 2005 Sep;33(3):195-201.

Back to Top

Autism and Gastrointestinal System

  • GI Pathology and Autism
  • Afzal N, Murch S, Thirrupathy K, Berger L, Fagbemi A, Heuschkel R. Constipation with acquired megarectum in children with autism. Pediatrics. 2003 Oct;112(4):939-42.
  • Alberti A, Pirrone P, Elia M, Waring R, Romano C. Sulphation deficit in “low-functioning” autistic children: a pilot study. Biol Psychiatry 1999; 46 (3), 420-424.
  • Ashwood P, Wakefield AJ. Immune activation of peripheral blood and mucosal CD3+ lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J Neuroimmunol. 2006 Apr;173(1-2):126-34.
  • Balzola F, Barbon V, Repici A, Rizzetto M. Panenteric IBD-like disease in a patient with regressive autism shown for the first time by the wireless capsule enteroscopy: another piece in the jigsaw of this gut-brain syndrome? Am J Gastro. 2005; 979-981.
  • Balzola F, Daniela C, Repici A, Barbon V, Sapino A, Barbera C, Calvo PL, Gandione M, Rigardetto R, Rizzetto M. Autistic enterocolitis: confirmation of a new inflammatory bowel disease in an Italian cohort of patients. Gastroenterology. 2005;128:Suppl.2;A-303.
  • Bolte ER. Autism and Clostridium tetani. Med Hypotheses. 1998 Aug;51(2):133-44.
  • Cade R, Privette M, Fregly M, Rowland N, Sun Z, Zele V, Wagemaker H, Edelstein C. Autism and schizophrenia: Intestinal disorders. Nutr Neurosci. 2000; 3, 57–72.
  • D’Eufemia P, Celli M, Finocchiaro R, Pacifico L, Viozzi L, Zaccagnini M, Cardi E, Giardini O. Abnormal intestinal permeability in children with autism. Acta Paediatr. 1996 Sep;85(9):1076-9.
  • Finegold SM, Molitoris D, Song Y, Liu C, Vaisanen ML, Bolte E, McTeague M, Sandler R, Wexler H, Marlowe EM, Collins MD, Lawson PA, Summanen P, Baysallar M, Tomzynski TJ, Read E, Johnson E, Rolfe R, Nasir P, Shah H, Haake DA, Manning P, Kaul A. Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis. 2002 Sep 1;35(Suppl 1):S6-S16.
  • Furlano RI, Anthony A, Day R, Brown A, McGavery L, Thomson MA, Davies SE, Berelowitz M, Forbes A, Wakefield AJ, Walker-Smith JA, Murch SH. Colonic CD8 and gamma delta T-cell infiltration with epithelial damage in children with autism. Pediatrics 2001;138:366-72.
  • Gonzalez L, Lopez K, Navarro D, Negron L, Flores L, Rodriguez R, Martinez M, Sabra A. Endoscopic and Histological Characteristics of the digestive mucosa in autistic children with gastrointestinal symptoms. Arch Venez Pueric Pediatr 69;1:19-25.
  • Goodwin MS, Cowen MA, Goodwin TC. Malabsorption and cerebral dysfunction. J Autism Child Schizophr. 1971;1:48-62.
  • Horvath K, Papadimitriou JC, Rabazlan A. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr 1999, 135:559-563.
  • Horvath K, Perman JA. Autistic disorder and gastrointestinal disease. Curr Opin Pediatr. 2002 Oct;14(5):583-7.
  • Knivsberg AM, Reichelt KL, Hoien T, Nodland M. A randomised, controlled study of dietary intervention in autistic syndromes. Nutr Neurosci. 2002 Sep;5(4):251-61.
  • Knivsberg AM, Reichelt KL, Nodland M, Hoein T: Autistic Syndromes and Diet: a follow-up study. Scandinavian Journal of Educational Research 1995; 39: 223-236.
  • Knivsberg AM, Reichelt KL, Nodland M. Reports on dietary intervention in autistic disorders. Nutr Neurosci. 2001;4(1):25-37.
  • Krigsman A, Boris M, Goldblatt A. Frequency of histologic enterocolitis and lymphonodular hyperplasia in autistic children presenting for ileocolonoscopy. IMFAR. May 7th, 2004.
  • Kuddo T, Nelson KB. How common are gastrointestinal disorders in children with autism. Curr Opin Pediatr 2003: 15(3); 339-343.
  • Kushak R, Winter H, Farber N, Buie T. Gastrointestinal symptoms and intestinal disaccharidase activities in children with autism. Abstract of presentation to the North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition, Annual Meeting, October 20-22, 2005, Salt Lake City, Utah.
  • Levy S, Souders MC, Wray J, Jawad AF, Gallagher PR, Coplan J, Belchic JK, Gerdes M, Mitchell R, Mulberg AE. Children with autistic spectrum disorders. I: Comparison of placebo and single dose of human synthetic secretin. Arch. Dis. Child. 2003;88;731-736.
  • Melmed RD, Schneider CK, Fabes RA. Metabolic markers and gastrointestinal symptoms in children with autism and related disorders. J Pediatr Gastroenterol Nutr 2000:31(suppl 2)S31-32.
  • Parent Ratings of Behavioral Effects of Biomedical Interventions. Autism Research Institute. www.autismwebsite.com/ari/treatment/form34q.htm.
  • Parracho HM, Bingham MO, Gibson GR, McCartney AL. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J Med Microbiol. 2005 Oct;54(Pt 10):987-91.
  • Reichelt KL, Knivsberg AM. Can the pathophysiology of autism be explained by the nature of the discovered urine peptides? Nutr Neurosci. 2003 Feb;6(1):19-28.
  • Reichelt KL, Knivsberg AM, Lind G, Nodland M: Probable Etiology and Possible Treatment of Childhood Autism. Brain Dysfuntion 1991; 4: 308-319.
  • Reichelt KL, Saelid G, Lindback T, Boler JB. Childhood autism: a complex disorder. Biol Psychiatry. 1986 Nov;21(13):1279-90.
  • Sandler RH, Finegold SM, Bolte ER, Buchanan CP, Maxwell AP, Vaisanen ML, Nelson MN, Wexler HM. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol. 2000 Jul;15(7):429-35.
  • Shattock P, Kennedy A, Rowell F, Berney T. Role of neuropeptides in autism and their relationship with classical neurotransmitters. Brain Dysfunction 1990:3: 328-345.
  • Shattock P, Lowdon G. Proteins, peptides and autism: Part 2: Implications for the education and care of people with autism. Brain Dysfunction. 1991;4: 323-334.
  • Shaw W, Kassen E, Chaves E. Increased urinary excretion of analogs of Krebs cycle metabolites and arabinose in two brothers with autistic features. Clin Chem. 1995 Aug;41(8 Pt 1):1094-104.
  • Song Y, Liu C, Finegold SM. Real-time PCR quantitation of clostridia in feces of autistic children. Appl Environ Microbiol. 2004 Nov;70(11):6459-65.
  • Taylor B, Miller E, Lingam R, Andrews N, Simmons A, Stowe J. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ. 2002 Feb 16;324(7334):393-6.
  • Torrente F, Machado N, Perez-Machado M, Furlano R, Thomson M, Davies S, Wakefield AJ, Walker-Smith JA, Murch SH. Enteropathy with T cell infiltration and epithelial IgG deposition in autism. Mol Psychiatry. 2002;7:375-382.
  • Torrente F, Anthony A. Focal-enhanced gastritis in regressive autism with features distinct from Crohn’s disease and helicobacter Pylori gastritis. Am J Gastroenterol 2004 Apr;99(4):598-605.
  • Valicenti-McDermott M, McVicar K, Rapin I, Wershil BK, Cohen H, Shinnar S. Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease. J Dev Behav Pediatr. 2006 Apr;27(2 Suppl):S128-36.
  • Wakefield AJ, Murch SH, Anthony A et al. Ileal-lymphoid nodular hyperplasia non-specific colitis and pervasive developmental disorder in children. Lancet. 1998;351:637-41.
  • Wakefield AJ, Puleston JM, Montgomery SM, Anthony A, O’Leary JJ, Murch SH. Review article: the concept of entero-colonic encephalopathy, autism and opioid receptor ligands. Aliment Pharmacol Ther. 2002 Apr;16(4):663-74.
  • Wakefield AJ, Anthony A, Murch SH, Thomson M, Montgomery SM, Davies S, O’Leary JJ, Berelowitz M, Walker-Smith JA. Enterocolitis in children with developmental disorders. Am J Gastroenterol. 2000 Sep;95(9):2285-95.
  • Wakefield AJ, Ashwood P, Limb K, Anthony A. The significance of ileo-colonic lymphoid nodular hyperplasia in children with autistic spectrum disorder. Eur J Gastroenterol Hepatol. 2005 Aug;17(8):827-36.
  • Walker SJ, Hepner K, Segal J, Krigsman A. Persistent ileal measles virus in a large cohort of regressive autistic children with ileocolitis and lymphonodular hyperplasia: revisitation of an earlier study. IMFAR. June 1, 2006.

Back to Top

Autism and the Detoxification System

  • Aschner M, Syversen T, Souza DO, Rocha JB. Metallothioneins: mercury species-specific induction and their potential role in attenuating neurotoxicity. Exp Biol Med (Maywood). 2006 Oct;231(9):1468-73.
  • Aw TY. Intestinal glutathione: determinant of mucosal peroxide transport, metabolism, and oxidative susceptibility. Toxicol Appl Pharmacol. 2005 May 1;204(3):320-8.
  • Boris M, Goldblatt A, Galanko J, James SJ. Association of MTHFR gene variants with autism. J Am Phys Surg. 2004: 9(4):106-108.
  • Cai J, Chen Y, Seth S, Furukawa S, Compans RW, Jones DP. Inhibition of influenza infection by glutathione. Free Radic Biol Med. 2003 Apr 1;34(7):928-36.
  • James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, Neubrander JA. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004 Dec;80(6):1611-7.
  • James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, Wong DH, Cutler P, Bock K, Boris M, Bradstreet JJ, Baker SM, Gaylor DW. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet. 2006 Aug 17.
  • Kern JK, Jones AM. Evidence of toxicity, oxidative stress, and neuronal insult in autism. J Toxicol Environ Health B Crit Rev. 2006 Nov-Dec;9(6):485-99.
  • Rimland B. Vitamin B6 (and magnesium) in the treatment of autism. Autism Research Review International, 1987, Vol. 1, No. 4, page 3.
  • Sido B, Hack V, Hochlehnert A, Lipps H, Herfarth C, Droge W. Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease. Gut. 1998 Apr;42(4):485-92.
  • Stubbs EG, Budden SS, Burger DR, Vandenbark AA. Transfer factor immunotherapy of an autistic child with congenital cytomegalovirus. J Autism Dev Disord. 1980 Dec;10(4):451-8.
  • Waly M, Olteanu H, Banerjee R, Choi SW, Mason JB, Parker BS, Sukumar S, Shim S, Sharma A, Benzecry JM, Power-Charnitsky VA, Deth RC. Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal. Mol Psychiatry. 2004 Apr;9(4):358-70.

Back to Top

Autism and Vaccines

Back to Top

Autism and Mercury

  • Thimerosal%20Safety
  • Pediatric MMR Vaccination Safety
  • MercuryBurdenInAutism
  • Mercury%20in%20Autism
  • Mercury in Children- case control study
  • Mercury Burden and Autism
  • merc exposure in children geier%201%20thimerosal
  • blood merc levels and autism
  • blood levels of Hg
  • Alexandre H, Delsinne V, Goval JJ, Van Cauwenberge A. Effect of taxol and okadaic acid on microtubule dynamics in thimerosal-arrested primary mouse oocytes: a confocal study. Biol Cell. 2003 Sep;95(6):407-14.
  • Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines. Pediatrics. 2001 May;107(5):1147-54.
  • Baskin DS, Ngo H, Didenko VV. Thimerosal induces DNA breaks, caspase-3 activation, membrane damage, and cell death in cultured human neurons and fibroblasts. Toxicol Sci. 2003 Aug;74(2):361-8.
  • Bernard S. Analysis of the Danish Autism Registry Data Base in Response to the Hviid et al. Paper on Thimerosal in JAMA. October, 2003.
  • Bernard S, Enayati A, Redwood L, Roger H, Binstock T. Autism: a novel form of mercury poisoning. Med Hypotheses. 2001 Apr;56(4):462-71.
  • Black J. The puzzle of pink disease. J R Soc Med. 1999 Sep;92(9):478-81.
  • Blair AMJN, Clark B, Clarke AJ, Wood P. Tissue concentrations of mercury after chronic dosing of squirrel monkeys with thiomersal. Toxicology. 1975;3(2):171-6.
  • Blaxill M. Danish Thimerosal-Autism Study in Pediatrics: Misleading and Uninformative on Autism-Mercury Link. Sep 2, 2003.
  • Bradstreet J, Geier DA, Kartzinel JJ, Adams JB, Geier MR. A case control study of mercury burden in children with autistic spectrum disorders. J Am Phys Surg. 2003;8(3):76.
  • Burbacher TM, Shen DD, Liberato N, Grant KS, Cernichiari E, Clarkson T. Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing thimerosal. Environ Health Perspect. 2005 Aug;113(8):1015-21.
  • Davidson PW, Myers GJ, Cox C, Axtell C, Shamlaye C, Sloane-Reeves J, Cernichiari E, Needham L, Choi A, Wang Y, Berlin M, Clarkson TW. Effects of prenatal and postnatal methylmercury exposure from fish consumption on neurodevelopment: outcomes at 66 months of age in the Seychelles Child Development Study. JAMA. 1998 Aug 26;280(8):701-7.
  • Davidson PW, Myers GJ, Weiss B. Mercury exposure and child development outcomes. Pediatrics. 2004;113(4 Suppl):1023-9.
  • Dally A. The rise and fall of pink disease. Soc Hist Med. 1997 Aug;10(2):291-304.
  • Ellefsen A, Kampmann H, Billstedt E, Gillberg IC, Gillberg C. Autism in the Faroe Islands. An Epidemiological Study. J Autism Dev Disord. 2006 Oct 7.
  • Engley FB Jr. Evaluation of mercurial compounds as antiseptics. Ann N Y Acad Sci. 1950 Aug;53(1):197-206.
  • Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics. 2006 Jul;118(1):e139-50.
  • Geier MR, Geier DA. An assessment of the impact of thimerosal on childhood neurodevelopmental disorders. Pediatr Rehabil. 2003 Apr-Jun;6(2):97-102.
  • Geier DA, Geier MR. A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-containing childhood vaccines on the population prevalence of autism. Med Sci Monit. 2004 Mar;10(3):PI33-9.
  • Goth SR, Chu RA, Gregg JP, Cherednichenko G, Pessah IN. Uncoupling of ATP-Mediated Calcium Signaling and Dysregulated Interleukin-6 Secretion in Dendritic Cells by Nanomolar Thimerosal. Environ Health Perspect. 2006 Jul;114(7):1083-91.
  • Grandjean P, Landrigan PJ. Developmental neurotoxicity of industrial chemicals. Lancet. 2006 Dec 16;368(9553):2167-78.
  • Grandjean P, Weihe P, White RF, Debes F, Araki S, Yokoyama K, Murata K, Sorensen N, Dahl R, Jorgensen PJ. Cognitive deficit in 7-year-old children with prenatal exposure to methylmercury. Neurotoxicol Teratol. 1997 Nov-Dec;19(6):417-28.
  • Havarinasab S, Hultman P. Organic mercury compounds and autoimmunity. Autoimmunity Rev 2005;4:270-275.
  • Havarinasab S, Haggqvist B, Bjorn E, Pollard KM, Hultman P. Immunosuppressive and autoimmune effects of thimerosal in mice. Toxicol Appl Pharmacol. 2005 Apr 15;204(2):109-21.
  • Holmes AS, Blaxill MF, Haley BE. Reduced levels of mercury in first baby haircuts of autistic children. Int J Toxicol. 2003 Jul-Aug;22(4):277-85.
  • Hornig M, Chian D, Lipkin WI. Neurotoxic effects of postnatal thimerosal are mouse strain dependent. Mol Psychiatry. 2004 Sep;9(9):833-45.
  • Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Association between thimerosal-containing vaccine and autism. JAMA. 2003 Oct 1;290(13):1763-6.
  • Institute of Medicine, Immunization Safety Review Committee, Thimerosal-containing vaccines and Neurodevelopmental Disorders, Oct. 1, 2001
  • Institute of Medicine, Immunization Safety Review: Vaccines and Autism. May 17, 2004.
  • James SJ, Slikker W 3rd, Melnyk S, New E, Pogribna M, Jernigan S. Thimerosal neurotoxicity is associated with glutathione depletion: protection with glutathione precursors. Neurotoxicology. 2005 Jan;26(1):1-8.
  • Kennedy, Robert, Jr. “Deadly Immunity.” salon.com June 16th, 2005.
  • Kirby, David. Evidence of Harm. St. Martin’s Press: 2005. P. 207.
  • Letter of July 22, 1935 from Director, Biological Laboratories of Pitman-Moore Company to W.A. Jamieson, Director, Biological Division, Eli Lilly & Company. Subcommittee on Human Rights and Wellness, Government Reform Committee. Mercury in Medicine Report, Washington, D.C. Congressional Record, May 21, 2003: E1011- 30.
  • Madsen KM, Lauritsen MB, Pedersen CB, Thorsen P, Plesner AM, Andersen PH, Mortensen PB. Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. Pediatrics. 2003p;112(3 Pt 1):604-6.
  • Magos L, Brown AW, Sparrow S, Bailey E, Snowden RT, Skipp WR. The comparative toxicology of ethyl- and methylmercury. Arch Toxicol. 1985 Sep;57(4):260-7.
  • Magos L. Neurotoxic character of thimerosal and the allometric extrapolation of adult clearance half-time to infants. J Appl Toxicol. 2003 Jul-Aug;23(4):263-9.
  • Magos L. Review on the toxicity of ethylmercury, including its presence as a preservative in biological and pharmaceutical products. J Appl Toxicol. 2001 Jan-Feb;21(1):1-5.
  • Mukhtarova ND. Late sequelae of nervous system pathology caused by the action of low concentrations of ethyl mercury chloride. Gig Tr Prof Zabol. 1977 Mar(3):4-7.
  • Makani S, Gollapudi S, Yel L, Chiplunkar S, Gupta S. Biochemical and molecular basis of thimerosal-induced apoptosis in T cells: a major role of mitochondrial pathway. Genes Immun. 2002 Aug;3(5):270-8.
  • Mutkus L, Aschner JL, Syversen T, Shanker G, Sonnewald U, Aschner M. In vitro uptake of glutamate in GLAST- and GLT-1-transfected mutant CHO-K1 cells is inhibited by the ethylmercury-containing preservative thimerosal. Biol Trace Elem Res. 2005 Summer;105(1-3):71-86.
  • Myers GJ, Davidson PW, Cox C, Shamlaye CF, Palumbo D, Cernichiari E, Sloane-Reeves J, Wilding GE, Kost J, Huang LS, Clarkson TW. Prenatal methylmercury exposure from ocean fish consumption in the Seychelles child development study. Lancet. 2003 May 17;361(9370):1686-92.
  • Nelson EA, Gottshall RY. Enhanced toxicity for mice of pertussis vaccines when preserved with Merthiolate. Appl Microbiol. 1967 May;15(3):590-3.
  • Palmer RF, Blanchard S, Stein Z, Mandell D, Miller C. Environmental mercury release, special education rates, and autism disorder: an ecological study of Texas. Health Place. 2006 Jun;12(2):203-9.
  • Parran DK, Barker A, Ehrich M. Effects of thimerosal on NGF signal transduction and cell death in neuroblastoma cells. Toxicol Sci. 2005 Jul;86(1):132-40.
  • Pichichero ME, Cernichiari E, Lopreiato J, Treanor J. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet. 2002 Nov 30;360(9347):1737-41.
  • Sanfeliu C, Sebastia J, Cristofol R, Rodriguez-Farre E. Neurotoxicity of organomercurial compounds. Neurotox Res. 2003;5(4):283-305.
  • Stajich GV, Lopez GP, Harry SW, Sexson WR. Iatrogenic exposure to mercury after hepatitis B vaccination in preterm infants. J Pediatr. 2000 May;136(5):679-81.
  • Transcript, “Scientific Review of Vaccine Safety Datalink Information,” Simpsonwood Retreat Center, Norcross, Georgia, June 7-8, 2000, at 31. Accessed online June 15, 2005 at www.nomercury.org/science/documents/Simpsonwood_Transcript.pdf, p.40
  • Ueha-Ishibashi T, Tatsuishi T, Iwase K, Nakao H, Umebayashi C, Nishizaki Y, Nishimura Y, Oyama Y, Hirama S, Okano Y. Property of thimerosal-induced decrease in cellular content of glutathione in rat thymocytes: a flow cytometric study with 5-chloromethylfluorescein diacetate. Toxicol In Vitro. 2004 Oct;18(5):563-9.
  • Ueha-Ishibashi T, Oyama Y, Nakao H, Umebayashi C, Nishizaki Y, Tatsuishi T, Iwase K, Murao K, Seo H. Effect of thimerosal, a preservative in vaccines, on intracellular Ca2+ concentration of rat cerebellar neurons. Toxicology. 2004 Jan 15;195(1):77-84.
  • Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005 Jan;57(1):67-81.
  • Verstraeten T, Davis RL, DeStefano F, Lieu TA, Rhodes PH, Black SB, Shinefield H, Chen RT; Vaccine Safety Datalink Team. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics. 2003 Nov;112(5):1039-48.
  • Verstraeten T. Thimerosal, the Centers for Disease Control and Prevention, and GlaxoSmithKline. Pediatrics. 2004;113;932.
  • Waly M, Olteanu H, Banerjee R, Choi SW, Mason JB, Parker BS, Sukumar S, Shim S, Sharma A, Benzecry JM, Power-Charnitsky VA, Deth RC. Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal. Mol Psychiatry. 2004 Apr;9(4):358-70.
  • Westphal GA, Asgari S, Schulz TG, Bunger J, Muller M, Hallier E. Thimerosal induces micronuclei in the cytochalasin B block micronucleus test with human lymphocytes. Arch Toxicol. 2003 Jan;77(1):50-5. Epub 2002 Nov 6.
  • Windham G, Zhang L, Gunier R, Croen L, Grether J. Autism Spectrum Disorders in Relation to Distribution of Hazardous Air Pollutants in the San Francisco Bay Area. Environ Health Perspect. 2006 Sep;114(9):1438-44.

Back to Top

Autism and Measles

  • Altmann D. Autism and measles, mumps, and rubella vaccine. Lancet 2000;355:409.
  • Bradstreet J, El Dahr J, Anthony A, Kartzinel J, Wakefield, A. Detection of Measles Virus Genomic RNA in Cerebrospinal Fluid of Children with Regressive Autism: a Report of Three Cases. J Am Phys Surg, Vol 9 No 2, 2004.
  • Chen W, Landau S, Sham P, Fombonne E. No evidence for links between autism, MMR and measles virus. Psychol Med. 2004 Apr;34(3):543-53.
  • Connolly J, Allen I, Hurwitz L, Millar JHD. Measles antibody and antigen in SSPE. Lancet 1967;i:542
  • Dales L, Hammer SJ, Smith NJ. Time trends in autism and MMR immunization coverage in California. JAMA. 2001;285:1183-1185.
  • DeWilde S, Carey IM, Richards N, Hilton SR, Cook DG. Do children who become autistic consult more often after MMR vaccination? Br J Gen Pract. 2001 Mar;51(464):226-7.
  • Edwardes M, Baltzan M. Measles, mumps, and rubella (MMR) vaccine and autism. Argument is too simplistic. BMJ. 2001 Jul 21;323(7305):163; author reply 164.
  • Edwardes M, Baltzan M. MMR Immunization and Autism. JAMA 2001;285:2852-3.
  • Freeman JM, Magoffin RL, Lennette EH, Herndon RM. Additional evidence of relation between subacute inclusion body encephalitis and measles virus. Lancet 1967;ii:129-131.
  • Garenne M, Leroy O, Bean J-P, Sene I, Child mortality after high titre measles vaccines: prospective study in Senegal. Lancet 1991;2:903-907.
  • Geier M, Geier D. Pediatric MMR Vaccination Safety. Int Pediatr. 2003:18/(2); 203-208.
  • Gillberg C, Heijbel H. MMR and autism. Autism. 1998;2:423-24.
  • Goin-Kochel RP, Mackintosh VH, Myers BJ. How many doctors does it take to make an autism spectrum diagnosis? Autism. 2006 Sep;10(5):439-51.
  • Goldman GS, Yazbak FE. An investigation of the association between MMR vaccination and autism in Denmark. J Am Phys Surg. 2004;9:70-75.
  • Honda H, Shimizu Y, Rutter M. No effect of MMR withdrawal on the incidence of autism: a total population study. J Child Psychol Psychiatry. 2005 Jun;46(6):572-9.
  • Immunization Safety Review Committee, Institute of Medicine. Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: National Academy Press; 2001.
  • Jirapinyo P, Thakernpol K, Chaichanwatanakul K. Cytopathic effects of measles virus on the human intestinal mucosa. J. Paed. Gastroenterol. Nutrit.1990;10:550-554.
  • Kawashima H, Mori T, Kashiwagi Y, Takekuma K, Hoshika A, Wakefield A. Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism. Dig Dis Sci. 2000 Apr;45(4):723-9.
  • Ki M, Park T, Gon Yi S, Kyoung Oh J, Youl Chi B. Risk Analysis of Aseptic Meningitis after Measles-Mumps-Rubella Vaccination in Korean Children by Using a Case-Crossover Design. Am J Epidemiol 2003; 157:158-165.
  • Landrigan PJ, Witte JJ. Neurologic disorders following live measles-virus vaccination. JAMA. 1973;223:1459-1462.
  • Lauritsen MB, Pedersen CB, Mortensen PB. The incidence and prevalence of pervasive developmental disorders: a Danish population-based study. Psychol Med. 2004;34:1339-1346.
  • Madsen KM, Hviid A, Vestergaard M, Schendel D, Wohlfahrt J, Thorsen P, Olsen J, Melbye M. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med. 2002 Nov 7;347(19):1477-82.
  • Makela A, Nuorti JP, Peltola H. Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics. 2002 Nov;110(5):957-63.
  • Miller E, Goldacre M, Pugh S, Colville A, Farrington P, Flower A, Nash J, MacFarlane L, Tettmar R. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet. 1993 Apr 17;341(8851):979-82.
  • Montgomery SM, Morris DL, Pounder RE, Wakefield AJ. Paramyxovirus infections in childhood and subsequent inflammatory bowel disease. Gastroenterology. 1999 Apr;116(4):796-803.
  • Patja A, Davidkin I, Kurki T, Kallio M, Valle M, Peltola H. Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up. Pediatr Infect Dis J. 2000;19:1127-34.
  • Peltola H, Patja A, Leinikki P, Valle M, Davidkin I, Paunio M. No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study. The Lancet. 1998; 351:1327-1328.
  • Plesner A-M, Hansen FJ, Taadon K, Nielson LH, Larsen CB, Pedersen E. Gait disturbance interpreted as cerebellar ataxia after MMR vaccination at 15 months of age: a follow-up study. Acta Paediatrica 2000;89:58-63.
  • Richler J, Luyster R, Risi S, Hsu WL, Dawson G, Bernier R, Dunn M, Hepburn S, Hyman SL, McMahon WM, Goudie-Nice J, Minshew N, Rogers S, Sigman M, Spence MA, Goldberg WA, Tager-Flusberg H, Volkmar FR, Lord C. Is There a ‘Regressive Phenotype’ of Autism Spectrum Disorder Associated with the Measles-Mumps-Rubella Vaccine? A CPEA Study. J Autism Dev Disord. 2006 Apr;36(3):299-316.
  • Rima BK, Duprex WP. Morbilliviruses and human disease. J Pathol. 2006 Jan;208(2):199-214.
  • Singh VK, Lin SX, Yang V. Serological association of measles virus and human herpesvirus-6 with brain autoantibodies in autism. Clin Immun Immunopathol. 1998 Oct:89(1):105-108.
  • Singh VK, Lin SX, Newell E, Nelson C. Abnormal measles-mumps-rubella antibodies and CNS autoimmunity in children with autism. J Biomed Sci. 2002;9:359-364.
  • Singh VK, Jensen RL. Elevated levels of measles antibodies in children with autism. Pediatr Neurol. 2003 Apr;28(4):292-4.
  • Smeeth L. Measles, mumps, and rubella (MMR) vaccine and autism: ecological studies cannot answer main question. BMJ 2001 Jul;323(7305):163.
  • Spitzer WO. Measles, mumps, and rubella vaccination and autism. N Engl J Med. 2003 Mar 6;348(10):951-4; author reply 951-4.
  • Stott C, Blaxill M, Wakefield A. MMR and Autism in Perspective: the Denmark story. J Am Phys Surg. 2004;9 (3): 89-91.
  • Takahashi H, Suzumura S, Shirakizawa F, Wada N, Tanaka-Taya K, Arai S, Okabe N, Ichikawa H, Sato T. An epidemiological study on Japanese autism concerning routine childhood immunization history. Jpn J Infect Dis. 2003 Jun;56(3):114-7.
  • Uhlmann V, Martin CM, Sheils O, Pilkington L, Silva I, Killalea A, Murch SB, Walker-Smith J, Thomson M, Wakefield AJ, O’Leary JJ. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. Mol Pathol. 2002 Apr;55(2):84-90.
  • Wakefield AJ. Enterocolitis, Autism and Measles Virus. Mol Psychiatry. 2002;7 Suppl 2:S44-6.
  • Wakefield AJ. Measles, mumps, and rubella vaccination and autism. N Engl J Med. 2003 Mar 6;348(10):951-4; author reply 951-4.
  • Wakefield AJ. MMR vaccination and autism. Lancet. 1999;354:949-50.
  • Wakefield AJ, Montgomery SM. Measles, mumps, rubella vaccine: through a glass, darkly. Adverse Drug React Toxicol Rev. 2000:19(4): 265–83.
  • Wakefield AJ, Murch SH, Anthony A, Linn ell J, Caisson DM, Mali M, Berelowitz M, Dhillon AP, Thomson MA, Harvey P, Valentine A, Davies SE, Walker-Smith JA: Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998 Feb 28;351(9103): 637-41.
  • Wakefield AJ., Puleston J. Montgomery SM., Anthony A., O’Leary J.J., Murch SH Entero-colonic encephalopathy, autism and opioid receptor ligands. Aliment Pharmacol Ther. 2002;16:663-674.
  • Wakefield A, Stott C, Limb K. Gastrointestinal comorbidity, autistic regression and Measles-containing vaccines: positive re-challenge and biological gradient. Medical Veritas: 3 (2006) 796–802.
  • Wakefield AJ, Stott C. No effect of MMR withdrawal on the incidence of autism: a total population study.
  • Walker SJ, Hepner K, Segal J, Krigsman A. Persistent ileal measles virus in a large cohort of regressive autistic children with ileocolitis and lymphonodular hyperplasia: revisitation of an earlier study. IMFAR.
  • Weibel RE, Caserta V, Benor DE. Acute encephalopathy followed by permanent brain injury or death associated with further attenuated measles vaccines: a review of claims submitted to the National Vaccine Injury Compensation Programme. Paediatrics 1998;101:383-387.
  • Wilson K, Mills E, Ross C, McGowan J, Jadad A. Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence. Arch Pediatr Adolesc Med. 2003 Jul;157(7):628-34.
  • Yazbak FE. Measles, mumps, and rubella (MMR) vaccine and autism. MMR cannot be exonerated without explaining increased incidence of autism. BMJ. 2001 Jul 21;323(7305):163-4.
  • Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)—United States, 1991-2001. MMWR Surveill Summ. 2003 Jan 24;52(1):1-24.

Back to Top

Autism and Porphyrinuria

Back to Top

Autism Therapies/Treatments

Back to Top

Correcting Nutritional Deficiencies

  • Adams JB, Holloway C. Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder. J Altern Complement Med. 2004 Dec;10(6):1033-9.
  • Adams JB, George F, Audhya T. Abnormally high plasma levels of vitamin B6 in children with autism not taking supplements compared to controls not taking supplements. J Altern Complement Med. 2006 Jan-Feb;12(1):59-63.
  • Aldred S, Moore KM, Fitzgerald M, Waring RH. Plasma amino acid levels in children with autism and their families. J Autism Dev Disord. 2003 Feb;33(1):93-7.
  • Ames BN, Elson-Schwab I, Silver EA. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased K (m)): relevance to genetic disease and polymorphisms. Am J Clin Nutr. 2002 Apr;75(4):616-58.
  • Amminger GP, Berger GE, Schafer MR, Klier C, Friedrich MH, Feucht M. Omega-3 Fatty Acids Supplementation in Children with Autism: A Double-blind Randomized, Placebo-controlled Pilot Study. Biol Psychiatry. 2006 Aug 22; [Epub ahead of print].
  • Arnold GL, Hyman SL, Mooney RA, Kirby RS. Plasma amino acids profiles in children with autism: potential risk of nutritional deficiencies. J Autism Dev Disord. 2003 Aug;33(4):449-54.
  • Baker SB, Worthley LI. The essentials of calcium, magnesium and phosphate metabolism: part I. Physiology. Crit Care Resusc. 2002 Dec;4(4):301-6.
  • Barthelemy C, Garreau B, Leddet I, Sauvage D, Domenech J, Muh JP, Lelord G. Biological and clinical effects of oral magnesium and associated magnesium-vitamin B6 administration on certain disorders observed in infantile autism. Therapie. 1980 Sep-Oct;35(5):627-32.
  • Bell JG, Sargent JR, Tocher DR, Dick JR. Red blood cell fatty acid compositions in a patient with autistic spectrum disorder: a characteristic abnormality in neurodevelopmental disorders? Prostaglandins Leukot Essent Fatty Acids. 2000 Jul-Aug;63(1-2):21-5.
  • Boris M, Goldblatt A, Galanko J, James SJ. Association of MTHFR gene variants with autism. J Am Phys Surg. 2004: 9(4):106-108.
  • Bronner F. Extracellular and intracellular regulation of calcium homeostasis. ScientificWorldJournal. 2001 Dec 22;1:919-25.
  • Bu B, Ashwood P, Harvey D, King IB, Water JV, Jin LW. Fatty acid compositions of red blood cell phospholipids in children with autism. Prostaglandins Leukot Essent Fatty Acids. 2006 Apr;74(4):215-21.
  • Calingasan NY, Huang PL, Chun HS, Fabian A, Gibson GE. Vascular factors are critical in selective neuronal loss in an animal model of impaired oxidative metabolism. J Neuropathol Exp Neurol. 2000 Mar;59(3):207-17.
  • Chez MG, Buchanan CP, Aimonovitch MC, Becker M, Schaefer K, Black C, Komen J. Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol. 2002 Nov;17(11):833-7.
  • Chugani DC, Sundram BS, Behen M, Lee ML, Moore GJ. Evidence of altered energy metabolism in autistic children. Prog Neuropsychopharmacol Biol Psychiatry. 1999 May;23(4):635-41.
  • Coleman M, Steinberg G, Tippett J, Bhagavan HN, Coursin DB, Gross M, Lewis C, DeVeau L. A preliminary study of the effect of pyridoxine administration in a subgroup of hyperkinetic children: a double-blind crossover comparison with methylphenidate. Biol Psychiatry. 1979 Oct;14(5):741-51.
  • Deluca HF. The vitamin D system: a view from basic science to the clinic. Clin Biochem. 1981 Oct;14(5):213-22.
  • Dhawan M, Kachru DN, Tandon SK. Influence of thiamine and ascorbic acid supplementation on the antidotal efficacy of thiol chelators in experimental lead intoxication. Arch Toxicol. 1988;62(4):301-4.
  • Dickinson VA, Block G, Russek-Cohen E. Supplement use, other dietary and demographic variables, and serum vitamin C in NHANES II. J Am Coll Nutr. 1994 Feb;13(1):22-32.
  • Dolske MC, Spollen J, McKay S, Lancashire E, Tolbert L. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry. 1993 Sep;17(5):765-74.
  • Fernstrom JD. Can nutrient supplements modify brain function? Am J Clin Nutr. 2000 Jun;71(6 Suppl):1669S-75S.
  • Filipek PA, Juranek J, Nguyen MT, Cummings C, Gargus JJ. Relative carnitine deficiency in autism. J Autism Dev Disord. 2004 Dec;34(6):615-23.
  • Friedman SD, Shaw DW, Artru AA, Richards TL, Gardner J, Dawson G, Posse S, Dager SR. Regional brain chemical alterations in young children with autism spectrum disorder. Neurology. 2003 Jan 14;60(1):100-7.
  • Gaull GE. Taurine in pediatric nutrition: review and update. Pediatrics. 1989 Mar;83(3):433-42.
  • Geoghegan M, McAuley D, Eaton S, Powell-Tuck J. Selenium in critical illness. Curr Opin Crit Care. 2006 Apr;12(2):136-41.
  • Goebel L, Driscoll H. Scurvy. www.emedicine.com. 7-15-05.
  • Grattan-Smith PJ, Wilcken B, Procopis PG, Wise GA. The neurological syndrome of infantile cobalamin deficiency: developmental regression and involuntary movements. Mov Disord. 1997 Jan;12(1):39-46.
  • Horvath K, Perman JA. Autistic disorder and gastrointestinal disease. Curr Opin Pediatr. 2002 Oct;14(5):583-7
  • Hunt C, Chakravorty NK, Annan G, Habibzadeh N, Schorah CJ. The clinical effects of vitamin C supplementation in elderly hospitalised patients with acute respiratory infections. Int J Vitam Nutr Res. 1994;64(3):212-9.
  • Imura K, Okada A. Amino acid metabolism in pediatric patients. Nutrition. 1998 Jan;14(1):143-8.
  • James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, Neubrander JA. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004 Dec;80(6):1611-7.
  • Johnson S. Micronutrient accumulation and depletion in schizophrenia, epilepsy, autism and Parkinson’s disease? Med Hypotheses. 2001 May;56(5):641-5.
  • Johnston CS, Thompson LL. Vitamin C status of an outpatient population. J Am Coll Nutr. 1998, 17(4)366-370.
  • Jonas C, Etienne T, Barthelemy C, Jouve J, Mariotte N. Clinical and biochemical value of Magnesium + vitamin B6 combination in the treatment of residual autism in adults. Therapie. 1984 Nov-Dec;39(6):661-9.
  • Kidd PM. Autism, an extreme challenge to integrative medicine. Part 2: medical management. Altern Med Rev. 2002 Dec;7(6):472-99.
  • Kleijnen J, Knipschild P. Niacin and vitamin B6 in mental functioning: a review of controlled trials in humans. Biol Psychiatry. 1991 May 1;29(9):931-41.
  • Kornreich L, Bron-Harlev E, Hoffmann C, Schwarz M, Konen O, Schoenfeld T, Straussberg R, Nahum E, Ibrahim AK, Eshel G, Horev G. Thiamine deficiency in infants: MR findings in the brain. Am J Neuroradiol. 2005 Aug;26(7):1668-74.
  • Kozielec T, Starobrat-Hermelin B. Assessment of magnesium levels in children with attention deficit hyperactivity disorder (ADHD). Magnes Res. 1997 Jun;10(2):143-8.
  • Kushak R, Winter W, Farber N, Buie T. Gastrointestinal symptoms and intestinal disaccharidase activities in children with autism. J Pediatr Gastroenterol Nutr. 2005 Oct: 41(4):508.
  • Lelord G, Muh JP, Barthelemy C, Martineau J, Garreau B, Callaway E. Effects of pyridoxine and magnesium on autistic symptoms—initial observations. J Autism Dev Disord. 1981 Jun;11(2):219-30.
  • Lelord G, Callaway E, Muh JP. Clinical and biological effects of high doses of vitamin B6 and magnesium on autistic children. Acta Vitaminol Enzymol. 1982;4(1-2):27-44.
  • Levy J. Immunonutrition: the pediatric experience. Nutrition. 1998 Jul-Aug;14(7-8):641-7.
  • Li J, Lin JC, Wang H, Peterson JW, Furie BC, Furie B, Booth SL, Volpe JJ, Rosenberg PA. Novel role of vitamin K in preventing oxidative injury to developing oligodendrocytes and neurons. J Neuroscience. 2003 Jul: 23(13):5816-5826.
  • Liebscher DH, Liebscher DE. About the misdiagnosis of magnesium deficiency. J Am Coll Nutr. 2004 Dec;23(6):730S-1S.
  • Litov RE, Combs GF Jr. Selenium in pediatric nutrition. Pediatrics. 1991 Mar;87(3):339-51.
  • Lonsdale D, Shamberger RJ, Audhya T. Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: a pilot study. Neuro Endocrinol Lett. 2002 Aug;23(4):303-8.
  • Mahadik SP, Scheffer RE. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 1996 Aug;55(1-2):45-54.
  • Martineau J, Barthelemy C, Garreau B, Lelord G. Vitamin B6, magnesium, and combined B6-Mg: therapeutic effects in childhood autism. Biol Psychiatry. 1985 May;20(5):467-78.
  • Megson MN. Is autism a G-alpha protein defect reversible with natural vitamin A? Med Hypotheses. 2000 Jun;54(6):979-83.
  • Moon J. The role of vitamin D in toxic metal absorption: a review. J Am Coll Nutr. 1994 Dec;13(6):559-64.
  • Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Vitamin B12 and folate depletion in cognition: a review. Neurol India. 2004 Sep;52(3):310-8.
  • Mousain-Bosc M, Roche M, Polge A, Pradal-Prat D, Rapin J, Bali JP. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. II. Pervasive developmental disorder-autism. Magnes Res. 2006 Mar;19(1):53-62.
  • Mousain-Bosc M, Roche M, Rapin J, Bali JP. Magnesium VitB6 intake reduces central nervous system hyperexcitability in children. J Am Coll Nutr. 2004 Oct;23(5):545S-548S.
  • Ohsaki Y, Shirakawa H, Hiwatashi K, Furukawa Y, Mizutani T, Komai M. Vitamin K suppresses lipopolysaccharide-induced inflammation in the rat. Biosci Biotechnol Biochem. 2006 Apr;70(4):926-32.
  • Olmez A, Yalcin S, Yurdakok K, Coskun T. Serum selenium levels in acute gastroenteritis of possible viral origin. J Trop Pediatr. 2004 Apr;50(2):78-81.
  • Pangborn J, Baker SM. Autism: Effective Biomedical Treatments (Have We Done Everything We Can For This Child? Individuality In An Epidemic). San Diego: Autism Research Institute; 2nd Edition Sept. 2005:232-235.
  • Pfeiffer CC, Braverman ER. Zinc, the brain and behavior. Biol Psychiatry. 1982 Apr;17(4):513-32.
  • Raiten DJ, Massaro T. Perspectives on the nutritional ecology of autistic children. J Autism Dev Disord. 1986 Jun;16(2):133-43.
  • Reddi K, Henderson B, Meghji S, Wilson M, Poole S, Hopper C, Harris M, Hodges SJ. Interleukin 6 production by lipopolysaccharide-stimulated human fibroblasts is potently inhibited by naphthoquinone (vitamin K) compounds. Cytokine. 1995 Apr;7(3):287-90.
  • Richardson AJ. Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry. 2006 Apr;18(2):155-72.
  • Rimland B. Controversies in the treatment of autistic children: vitamin and drug therapy. J Child Neurol. 1988;3 Suppl:S68-72.
  • Rimland, B. High dosage levels of certain vitamins in the treatment of children with severe mental disorders. In D. Hawkins & L. Pauling (Eds.), Orthomolecular Psychiatry . 1973 (pp. 513-538).
  • Rimland B, Callaway E, Dreyfus P. The effect of high doses of vitamin B6 on autistic children: a double-blind crossover study. Am J Psychiatry. 1978 Apr;135(4):472-5.
  • Rosenberg IH. Folic acid and neural-tube defects—time for action? N Engl J Med. 1992 Dec 24;327(26):1875-7.
  • Schectman G, Byrd JC, Hoffmann R. Ascorbic acid requirements for smokers: analysis of a population survey. Am J Clin Nutr. 1991 Jun;53(6):1466-70.
  • Schoon EJ, Muller MC, Vermeer C, Schurgers LJ, Brummer RJ, Stockbrugger RW. Low serum and bone vitamin K status in patients with longstanding Crohn’s disease: another pathogenetic factor of osteoporosis in Crohn’s disease? Gut. 2001 Apr;48(4):473-7.
  • Schorah CJ, Downing C, Piripitsi A, Gallivan L, Al-Hazaa AH, Sanderson MJ, Bodenham A. Total vitamin C, ascorbic acid, and dehydroascorbic acid concentrations in plasma of critically ill patients. Am J Clin Nutr. 1996 May;63(5):760-5.
  • Singh RB, Niaz MA, Agarwal P, Begom R, Rastogi SS. Effect of antioxidant-rich foods on plasma ascorbic acid, cardiac enzyme, and lipid peroxide levels in patients hospitalized with acute myocardial infarction. J Am Diet Assoc. 1995 Jul;95(7):775-80.
  • Sogut S, Zoroglu SS, Ozyurt H, Yilmaz HR, Ozugurlu F, Sivasli E, Yetkin O, Yanik M, Tutkun H, Savas HA, Tarakcioglu M, Akyol O. Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clin Chim Acta. 2003 May;331(1-2):111-7.
  • Starobrat-Hermelin B, Kozielec T. The effects of magnesium physiological supplementation on hyperactivity in children with attention deficit hyperactivity disorder (ADHD). Positive response to magnesium oral loading test. Magnes Res. 1997 Jun;10(2):149-56.
  • Sturman JA, Chesney RW. Taurine in pediatric nutrition. Pediatr Clin North Am. 1995 Aug;42(4):879-97.
  • Sugiura I, Furie B, Walsh CT, Furie BC. Propeptide and glutamate-containing substrates bound to the vitamin K-dependent carboxylase convert its vitamin K epoxidase function from an inactive to an active state. Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9069-74.
  • Tchantchou F, Graves M, Shea TB. Expression and activity of methionine cycle genes are altered following folate and vitamin E deficiency under oxidative challenge: modulation by apolipoprotein E-deficiency. Nutr Neurosci. 2006 Feb-Apr;9(1-2):17-24.
  • Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci. 2001 Apr;22(4):195-201.
  • Vancassel S, Durand G, Barthelemy C, Lejeune B, Martineau J, Guilloteau D, Andres C, Chalon S. Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids. 2001 Jul;65(1):1-7.
  • Van Gelder NM, Sherwin AL, Sacks C, Anderman F. Biochemical observations following administration of taurine to patients with epilepsy. Brain Res. 1975 Aug 29;94(2):297-306.
  • Vervoort LM, Ronden JE, Thijssen HH. The potent antioxidant activity of the vitamin K cycle in microsomal lipid peroxidation. Biochem Pharmacol. 1997 Oct 15;54(8):871-6.
  • Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, Berelowitz M, Dhillon AP, Thomson MA, Harvey P, Valentine A, Davies SE, Walker-Smith JA. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998 Feb 28;351(9103):637-41.
  • Walsh WJ, Glab LB, Haakenson ML. Reduced violent behavior following biochemical therapy. Physiol Behav. 2004 Oct 15;82(5):835-9.
  • Waring RH, Klovrza LV. Sulphur metabolism in autism. J Nutr Env Med. 2000:10:25-35.
  • White JF. Intestinal pathophysiology in autism. Exp Biol Med (Maywood). 2003 Jun;228(6):639-49.
  • Whiteley P, Waring R, Williams L, Klovrza L, Nolan F, Smith S, Farrow M, Dodou K, Lough WJ, Shattock P. Spot urinary creatinine excretion in pervasive developmental disorders. Pediatr Int. 2006 Jun;48(3):292-7.
  • Whiting SJ, Calvo MS. Dietary recommendations for vitamin D: a critical need for functional end points to establish an estimated average requirement. J Nutr. 2005 Feb;135(2):304-9.
  • Young G, Conquer J. Omega-3 fatty acids and neuropsychiatric disorders. Reprod Nutr Dev. 2005 Jan-Feb;45(1):1-28.
  • Zitterman A. Effects of vitamin K on calcium and bone metabolism. Curr Opin Clin Nutr Metab Care. 2001 Nov 4(6):483-487.
  • Zoroglu SS, Yurekli M, Meram I, Sogut S, Tutkun H, Yetkin O, Sivasli E, Savas HA, Yanik M, Herken H, Akyol O. Pathophysiological role of nitric oxide and adrenomedullin in autism. Cell Biochem Funct. 2003 Mar;21(1):55-60.

Back to Top

Treating the Gut

  • Afzal N, Murch S, Thirrupathy K, Berger L, Fagbemi A, Heuschkel R. Constipation with acquired megarectum in children with autism. Pediatrics. 2003 Oct;112(4):939-42.
  • Aldred S, Moore KM, Fitzgerald M, Waring RH. Plasma amino acid levels in children with autism and their families. J Autism Dev Disord. 2003 Feb;33(1):93-7.
  • Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. N Engl J Med. 1996 Jun 13;334(24):1557-60.
  • Biller JA, Katz AJ, Flores AF, Buie TM, Gorbach SL. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr. 1995 Aug;21(2):224-6.
  • Bousvaros A, Sylvester F, Kugathasan S, Szigethy E, Fiocchi C, Colletti R, Otley A, Amre D, Ferry G, Czinn SJ, Splawski JB, Oliva-Hemker M, Hyams JS, Faubion WA, Kirschner BS, Dubinsky MC; and the Members of the Challenges in Pediatric IBD Study Groups. Challenges in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2006 Sep;12(9):885-913.
  • Buts JP, De Keyser N, De Raedemaeker L. Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines. Pediatr Res. 1994 Oct;36(4):522-7.
  • Buts JP, De Keyser N. Effects of Saccharomyces boulardii on intestinal mucosa. Dig Dis Sci. 2006 Aug;51(8):1485-92.
  • Buts JP, De Keyser N, Marandi S, Hermans D, Sokal EM, Chae YH, Lambotte L, Chanteux H, Tulkens PM. Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats. Gut. 1999 Jul;45(1):89-96.
  • Gottschall, Elaine G. Breaking the Vicious Cycle: Intestinal Health Through Diet. Ontario: Kirkton Press. 1994.
  • Haskey N, Dahl WJ. Synbiotic therapy: a promising new adjunctive therapy for ulcerative colitis. Nutr Rev. 2006 Mar;64(3):132-8.
  • Hassall E. Decisions in diagnosing and managing chronic gastroesophageal reflux disease in children. J Pediatr. 2005 Mar;146(3 Suppl):S3-12.
  • Homan M, Baldassano RN, Mamula P. Managing complicated Crohn’s disease in children and adolescents. Nat Clin Pract Gastroenterol Hepatol. 2005 Dec;2(12):572-9.
  • Horvath K, Papadimitriou JC, Rabsztyn A, Drachenberg C, Tildon JT. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr. 1999 Nov;135(5):559-63.
  • Horvath KD, Jobe BA, Herron DM, Swanstrom LL. Laparoscopic Toupet fundoplication is an inadequate Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics. 1991 Jul;88(1):90-7.
  • Itoh T, Fujimoto Y, Kawai Y, Toba T, Saito T. Inhibition of food-borne pathogenic bacteria by bacteriocins from Lactobacillus gasseri. Lett Appl Microbiol. 1995 Sep;21(3):137-41.
  • Kaila M, Isolauri E, Soppi E, Virtanen E, Laine S, Arvilommi H. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res. 1992 Aug;32(2):141-4.
  • Kushak R, Winter H, Farber N, Buie T. Gastrointestinal symptoms and intestinal disaccharidase activities in children with autism. J Pediatr Gastroenterol Nutr. 2005 Oct;41(4).
  • Levy J. Immunonutrition: the pediatric experience. Nutrition. 1998 Jul-Aug;14(7-8):641-7.
  • Lin MY, Savaiano D, Harlander S. Influence of nonfermented dairy products containing bacterial starter cultures on lactose maldigestion in humans. J Dairy Sci. 1991 Jan;74(1):87-95.
  • Liu Z, Li N, Neu J. Tight junctions, leaky intestines, and pediatric diseases. Acta Paediatr. 2005 Apr;94(4):386-93.
  • Macdonald A. Omega-3 fatty acids as adjunctive therapy in Crohns disease. Gastroenterol Nurs. 2006 Jul-Aug;29(4):295-301.
  • Majamaa H, Isolauri E, Saxelin M, Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr. 1995 Apr;20(3):333-8.
  • North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Evaluation and treatment of constipation in children: summary of updated recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2006 Sep;43(3):405-7.
  • Reichelt KL, Knivsberg AM. Can the pathophysiology of autism be explained by the nature of the discovered urine peptides? Nutr Neurosci. 2003 Feb;6(1):19-28.
  • Romano C, Cucchiara S, Barabino A, Annese V, Sferlazzas C. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn’s disease: a double-blind, randomized, placebo-controlled study. World J Gastroenterol. 2005 Dec 7;11(45):7118-21.
  • Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet. 1994 Oct 15;344(8929):1046-9.
  • Schneider CK, Melmed RD, Barstow LE, Enriquez FJ, Ranger-Moore J, Ostrem JA. Oral Human Immunoglobulin for Children with Autism and Gastrointestinal Dysfunction: A Prospective, Open-Label Study. J Autism Dev Disord. 2006 Jul 15.
  • Shermak MA, Saavedra JM, Jackson TL, Huang SS, Bayless TM, Perman JA. Effect of yogurt on symptoms and kinetics of hydrogen production in lactose-malabsorbing children. Am J Clin Nutr. 1995 Nov;62(5):1003-6.
  • Sougioultzis S, Simeonidis S, Bhaskar KR, Chen X, Anton PM, Keates S, Pothoulakis C, Kelly CP. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun. 2006 Apr 28;343(1):69-76.
  • Sutas Y, Hurme M, Isolauri E. Down-regulation of anti-CD3 antibody-induced IL-4 production by bovine caseins hydrolysed with Lactobacillus GG-derived enzymes. Scand J Immunol. 1996 Jun;43(6):687-9.
  • Torrente F, Ashwood P, Day R, Machado N, Furlano RI, Anthony A, Davies SE, Wakefield AJ, Thomson MA, Walker-Smith JA, Murch SH. Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Mol Psychiatry. 2002;7(4):375-82, 334.
  • Torrente F, Anthony A, Heuschkel RB, Thomson MA, Ashwood P, Murch SH. Focal-enhanced gastritis in regressive autism with features distinct from Crohn’s and Helicobacter pylori gastritis. Am J Gastroenterol. 2004 Apr;99(4):598-605.
  • Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci. 2001 Apr;22(4):195-201.
  • Waring RH, Klovrza LV. Sulphur metabolism in autism. J Nutr Env Med. 2000;10,25-32. Procedure for patients with severe reflux disease. J Gastrointest Surg. 1999 Nov-Dec;3(6):583-91.
  • Working Group of the Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition; Konno M, Kobayashi A, Tomomasa T, Kaneko H, Toyoda S, Nakazato Y, Nezu R, Maisawa S, Miki K. Guidelines for the treatment of Crohn’s disease in children. Pediatr Int. 2006 Jun;48(3):349-52.

Back to Top

Detoxification

  • Alberti A, Pirrone P, Elia M, Waring RH, Romano C. Sulphation deficit in “low-functioning” autistic children: a pilot study. Biol Psychiatry. 1999 Aug 1;46(3):420-4.
  • Arosio E, De Marchi S, Zannoni M, Prior M, Lechi A. Effect of glutathione infusion on leg arterial circulation, cutaneous microcirculation, and pain-free walking distance in patients with peripheral obstructive arterial disease: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2002 Aug;77(8):754-9.
  • Aw TY, Wierzbicka G, Jones DP. Oral glutathione increases tissue glutathione in vivo. Chem Biol Interact. 1991;80(1):89-97.
  • Bagnato GF, Gulli S, De Pasquale R, Giacobbe O, Spatari G, Purello D’Ambrosio F. Effect of inhaled glutathione on airway response to ‘Fog’ challenge in asthmatic patients. Respiration. 1999 Nov-Dec;66(6):518-21.
  • Bellinger DC. Lead. Pediatrics. 2004 Apr;113(4 Suppl):1016-22.
  • Bellinger DC, Bellinger AM. Childhood lead poisoning: the torturous path from science to policy. J Clin Invest. 2006 Apr;116(4):853-7.
  • Blanusa M, Varnai VM, Piasek M, Kostial K. Chelators as antidotes of metal toxicity: therapeutic and experimental aspects. Curr Med Chem. 2005;12(23):2771-94.
  • Boris M, Goldblatt A, Galanko J, James J. Association of MTHFR gene variants with autism. J Am Phys Surg. 2004;9(4)106-8.
  • Borok Z, Buhl R, Grimes GJ, Bokser AD, Hubbard RC, Holroyd KJ, Roum JH, Czerski DB, Cantin AM, Crystal RG. Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet. 1991 Jul 27;338(8761):215-6.
  • Brown MJ, Willis T, Omalu B, Leiker R. Deaths resulting from hypocalcemia after administration of edetate disodium: 2003-2005. Pediatrics. 2006 Aug;118(2):e534-6.
  • Buhl R, Vogelmeier C, Critenden M, Hubbard RC, Hoyt RF Jr, Wilson EM, Cantin AM, Crystal RG. Augmentation of glutathione in the fluid lining the epithelium of the lower respiratory tract by directly administering glutathione aerosol. Proc Natl Acad Sci U S A. 1990 Jun;87(11):4063-7.
  • Butterworth RF, Gonce M, Barbeau A. Accumulation and removal of Hg203 in different regions of the rat brain. Can J Neurol Sci. 1978 Nov;5(4):397-400.
  • Chauhan V, Chauhan A. Oxidative stress in Alzheimer’s disease. Pathophysiology. 2006 Aug;13(3):195-208.
  • Chauhan A, Chauhan V, Brown WT, Cohen I. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin—the antioxidant proteins. Life Sci. 2004 Oct 8;75(21):2539-49.
  • Connors SL, Crowell DE. Secretin and autism: the role of cysteine. J Am Acad Child Adolesc Psychiatry. 1999 Jul;38(7):795-6.
  • Dietrich KN, Ware JH, Salganik M, Radcliffe J, Rogan WJ, Rhoads GG, Fay ME, Davoli CT, Denckla MB, Bornschein RL, Schwarz D, Dockery DW, Adubato S, Jones RL; Treatment of Lead-Exposed Children Clinical Trial Group. Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry. Pediatrics. 2004 Jul;114(1):19-26.
  • Favilli F, Marraccini P, Iantomasi T, Vincenzini MT. Effect of orally administered glutathione on glutathione levels in some organs of rats: role of specific transporters. Br J Nutr. 1997 Aug;78(2):293-300.
  • Flora SJ, Pande M, Kannan GM, Mehta A. Lead induced oxidative stress and its recovery following co-administration of melatonin or N-acetylcysteine during chelation with succimer in male rats. Cell Mol Biol (Noisy-le-grand). 2004;50 Online Pub:OL543-51.
  • Forman J, Moline J, Cernichiari E, Sayegh S, Torres JC, Landrigan MM, Hudson J, Adel HN, Landrigan PJ. A cluster of pediatric metallic mercury exposure cases treated with meso-2,3-dimercaptosuccinic acid (DMSA). Environ Health Perspect. 2000 Jun;108(6):575-7.
  • Golse B, Debray-Ritzen P, Durosay P, Puget K, Michelson AM. Alterations in two enzymes: superoxide dismutase and glutathione peroxidase in developmental infantile psychosis (infantile autism). Rev Neurol (Paris). 1978 Nov;134(11):699-705.
  • Goyer RA, Cherian MG, Jones MM, Reigart JR. Role of chelating agents for prevention, intervention, and treatment of exposures to toxic metals. Environ Health Perspect. 1995 Nov;103(11):1048-52.
  • Graziano JH, Lolacono NJ, Moulton T, Mitchell ME, Slavkovich V, Zarate C. Controlled study of meso-2,3-dimercaptosuccinic acid for the management of childhood lead intoxication. J Pediatr. 1992 Jan;120(1):133-9.
  • Holmes AS, Blaxill MF, Haley BE. Reduced levels of mercury in first baby haircuts of autistic children. Int J Toxicol. 2003 Jul-Aug;22(4):277-85.
  • Holroyd KJ, Buhl R, Borok Z, Roum JH, Bokser AD, Grimes GJ, Czerski D, Cantin AM, Crystal RG. Correction of glutathione deficiency in the lower respiratory tract of HIV seropositive individuals by glutathione aerosol treatment. Thorax. 1993 Oct;48(10):985-9.
  • Horvath K, Papadimitriou JC, Rabsztyn A, Drachenberg C, Tildon JT. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr. 1999 Nov;135(5):559-63.
  • Hudson VM. New insights into the pathogenesis of cystic fibrosis: pivotal role of glutathione system dysfunction and implications for therapy. Treat Respir Med. 2004;3(6):353-63.
  • Hunjan MK, Evered DF. Absorption of glutathione from the gastro-intestinal tract. Biochim Biophys Acta. 1985 May 14;815(2):184-8.
  • James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, Neubrander JA. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004 Dec;80(6):1611-7.
  • James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, Wong DH, Cutler P, Bock K, Boris M, Bradstreet JJ, Baker SM, Gaylor DW. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet. 2006 Aug 17.
  • James SJ, Slikker W 3rd, Melnyk S, New E, Pogribna M, Jernigan S. Thimerosal neurotoxicity is associated with glutathione depletion: protection with glutathione precursors. Neurotoxicology. 2005 Jan;26(1):1-8.
  • Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, Sanacora G, Krystal JH, Coric V. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl). 2006 Jan;184(2):254-6.
  • Lanphear BP, Hornung R, Khoury J, Yolton K, Baghurst P, Bellinger DC, Canfield RL, Dietrich KN, Bornschein R, Greene T, Rothenberg SJ, Needleman HL, Schnaas L, Wasserman G, Graziano J, Roberts R. Low-level environmental lead exposure and children’s intellectual function: an international pooled analysis. Environ Health Perspect. 2005 Jul;113(7):894-9.
  • Mayer M, Noble M. N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7496-500.
  • McGuiness W. Oxidative stress in autism. Alternative Therapies. 2004;10(6):22-37.
  • Melhem A, Stern M, Shibolet O, Israeli E, Ackerman Z, Pappo O, Hemed N, Rowe M, Ohana H, Zabrecky G, Cohen R, Ilan Y. Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. J Clin Gastroenterol. 2005 Sep;39(8):737-42.
  • Miller AL. Dimercaptosuccinic acid (DMSA), a non-toxic, water-soluble treatment for heavy metal toxicity. Altern Med Rev. 1998 Jun;3(3):199-207.
  • Ming X, Stein TP, Brimacombe M, Johnson WG, Lambert GH, Wagner GC. Increased excretion of a lipid peroxidation biomarker in autism. Prostaglandins Leukot Essent Fatty Acids. 2005 Nov;73(5):379-84.
  • Nataf R, Skorupka C, Amet L, Lam A, Springbett A, Lathe R. Porphyrinuria in childhood autistic disorder: implications for environmental toxicity. Toxicol Appl Pharmacol. 2006 Jul 15;214(2):99-108.
  • Oka S, Kamata H, Kamata K, Yagisawa H, Hirata H. N-acetylcysteine suppresses TNF-induced NF-kappaB activation through inhibition of IkappaB kinases. FEBS Lett. 2000 Apr 28;472(2-3):196-202
  • Pangborn J, Baker SM. Autism: Effective Biomedical Treatments (Have We Done Everything We Can For This Child? Individuality In An Epidemic). Second ed. San Diego: Autism Research Institute, 2005:299-301.
  • Pasca SP, Nemes B, Vlase L, Gagyi CE, Dronca E, Miu AC, Dronca M. High levels of homocysteine and low serum paraoxonase 1 arylesterase activity in children with autism. Life Sci. 2006 Apr 4;78(19):2244-8.
  • Planas-Bohne F. The effect of 2,3-dimercaptorpropane-1-sulfonate and dimercaptosuccinic acid on the distribution and excretion of mercuric chloride in rats. Toxicology. 1981;19(3):275-8.
  • Roum JH, Borok Z, McElvaney NG, Grimes GJ, Bokser AD, Buhl R, Crystal RG. Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis. J Appl Physiol. 1999 Jul;87(1):438-43.
  • Schauer RJ, Kalmuk S, Gerbes AL, Leiderer R, Meissner H, Schildberg FW, Messmer K, Bilzer M. Intravenous administration of glutathione protects parenchymal and non-parenchymal liver cells against reperfusion injury following rat liver transplantation. World J Gastroenterol. 2004 Mar 15;10(6):864-70.
  • Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM, Rosati G. Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 1996 Oct;20(7):1159-70.
  • Sogut S, Zoroglu SS, Ozyurt H, Yilmaz HR, Ozugurlu F, Sivasli E, Yetkin O, Yanik M, Tutkun H, Savas HA, Tarakcioglu M, Akyol O. Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clin Chim Acta. 2003 May;331(1-2):111-7.
  • Stangle DE, Smith DR, Beaudin SA, Strawderman MS, Levitsky DA, Strupp BJ. Succimer chelation improves learning, attention and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure. Environ Health Perspect. doi:10.1289/ehp.9263 [Online 30 October 2006].
  • Testa B, Testa D, Mesolella M, D’Errico G, Tricarico D, Motta G. Management of chronic otitis media with effusion: the role of glutathione. Laryngoscope. 2001 Aug;111(8):1486-9.
  • Walsh WJ, Glab LB, Haakenson ML. Reduced violent behavior following biochemical therapy. Physiol Behav. 2004 Oct 15;82(5):835-9.
  • Waring RH, Klovrza LV. Sulphur metabolism in autism. J Nutr Env Med. 2000;10:25-32.
  • Waring RH., Ngong JM., Klovrza L., Green S., Sharp H. Biochemical parameters in autistic children. Dev Brain Dysfunction. 1997;10:40-43.
  • Wegmann K. Chelation therapy to treat lead toxicity in children. Minn Med. 1992 Nov;75(11):25-7.
  • Yorbik O, Sayal A, Akay C, Akbiyik DI, Sohmen T. Investigation of antioxidant enzymes in children with autistic disorder. Prostaglandins Leukot Essent Fatty Acids. 2002 Nov;67(5):341-3.
  • Zoroglu SS, Armutcu F, Ozen S, Gurel A, Sivasli E, Yetkin O, Meram I. Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism. Eur Arch Psychiatry Clin Neurosci. 2004 Jun;254(3):143-7.
  • Zoroglu SS, Yurekli M, Meram I, Sogut S, Tutkun H, Yetkin O, Sivasli E, Savas HA, Yanik M, Herken H, Akyol O. Pathophysiological role of nitric oxide and adrenomedullin in autism. Cell Biochem Funct. 2003 Mar;21(1):55-60.

Back to Top

Treating the Immune System

  • Agrawal YP. Low dose naltrexone therapy in multiple sclerosis. Med Hypotheses. 2005;64(4):721-4.
  • Bayary J, Dasgupta S, Misra N, Ephrem A, Van Huyen JP, Delignat S, Hassan G, Caligiuri G, Nicoletti A, Lacroix-Desmazes S, Kazatchkine MD, Kaveri S. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int Immunopharmacol. 2006 Apr;6(4):528-34.
  • Boris M, Goldblatt A, Edelson S. Improvement in children treated with intravenous gamma globulin. J Nutr Environmental Med. Dec 2006; 15(4):1-8.
  • Boris M, Kaiser C, Goldblatt A, Elice MW, Edelson SM, Feinstein DL. Effect of Pioglitazone treatment on behavioral symptoms in autistic children. J Neuroinflammation. 2007 Jan 5;4:3.
  • Bradstreet JJ, Smith S, Granpeesheh D, El-Dahr JM, Rossignol D. Spironolactone Might be a Desirable Immunologic and Hormonal Intervention in Autism Spectrum Disorders. Med Hypotheses. 2006 Dec 4.
  • Bradstreet JJ, El Dahr JM, Anthony A, Kartzinel JJ, Wakefield AJ. Detection of measles virus genomic RNA in cerebrospinal fluid of children with regressive autism: a report of three cases. J Am Phys Surg. 2004:9(2):38-45.
  • Chinetti G, Fruchart JC, Staels B. Peroxisome proliferators-activated receptors (PPAR): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000;49:497-505.
  • DelGiudice-Asch G, Simon L, Schmeidler J, Cunningham-Rundles C, Hollander E. Brief report: A pilot open clinical trial of intravenous immunoglobulin in childhood autism. J Autism Dev Disord. 1999:29(2):157-60.
  • Douglass JA, O’Hehir RE. 1. Diagnosis, treatment and prevention of allergic disease: the basics. Med J Aust. 2006 Aug 21;185(4):228-33.
  • Ebina T, Sato A, Umezu K, Aso H, Ishida N, Seki H, Tsukamoto T, Takase S, Hoshi S, Ohta M. Treatment of multiple sclerosis with anti-measles cow colostrum. Med Microbiol Immunol (Berl). 1984;173(2):87-93.
  • Elchaar GM, Maisch NM, Augusto LM, Wehring HJ. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Ann Pharmacother. 2006 Jun;40(6):1086-95.
  • Estrada-Parra S, Nagaya A, Serrano E, Rodriguez O, Santamaria V, Ondarza R, Chavez R, Correa B, Monges A, Cabezas R, Calva C, Estrada-Garcia I. Comparative study of transfer factor and acyclovir in the treatment of herpes zoster. Int J Immunopharmacol. 1998 Oct;20(10):521-35.
  • Feinstein DL. Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol Ther. 2003;5(1):67-73.
  • Flores Sandoval G, Gomez Vera J, Orea Solano M, Lopez Tiro J, Serrano E, Rodriguez A, Rodriguez A, Estrada Parra S, Jimenez Saab N. Transfer factor as specific immunomodulator in the treatment of moderate-severe atopic dermatitis. Rev Alerg Mex. 2005 Nov-Dec;52(6):215-20.
  • Fudenberg HH. Dialysable lymphocyte extract (DLyE) in infantile onset autism: a pilot study. Biotherapy. 1996;9(1-3):143-7.
  • Geier DA, Geier MR. A Clinical and Laboratory Evaluation of Methionine Cycle-Transsulfuration and Androgen Pathway Markers in Children with Autistic Disorders. Horm Res. 2006 Jul 5;66(4):182-188.
  • Good P. Low-dose naltrexone for multiple sclerosis and autism: does its benefit reveal a common cause? Med Hypotheses. 2006;67(3):671-2.
  • Gupta S. Immunological treatments for autism. J Autism Dev Disord. 2000 Oct;30(5):475-9.
  • Gupta S, Aggarwal S, Heads C. Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics. J Autism Dev Disord. 1996 Aug;26(4):439-52.
  • Inestrosa NC, Godoy JA, Quintanilla RA, Koenig CS, Bronfman M. Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling. Exp Cell Res. 2005 Mar 10;304(1):91-104.
  • James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, Neubrander JA. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004 Dec;80(6):1611-7.
  • Keating MR. Antiviral agents for non-human immunodeficiency virus infections. Mayo Clin Proc. 1999 Dec;74(12):1266-83.
  • Kelly GS. Bovine colostrums: a review of clinical uses. Altern Med Rev. 2003 Nov;8(4):378-94.
  • Kidd PM. Autism, an extreme challenge to integrative medicine. Part 2: medical management. Altern Med Rev. 2002 Dec;7(6):472-99.
  • Knickmeyer R, Baron-Cohen S, Raggatt P, Taylor K. Foetal testosterone, social relationships, and restricted interests in children. J Child Psychol Psychiatry. 2005 Feb;46(2):198-210.
  • Koski CL, Patterson JV. Intravenous immunoglobulin use for neurologic diseases. J Infus Nurs. 2006 May-Jun;29(3 Suppl):S21-8.
  • Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie EJ, Hurd LB, Su CG, Keilbaugh SA, Lazar MA, Wu GD. An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol. 2001 Dec;96(12):3323-8.
  • Meffert M, Baltimore D. Physiological Functions of brain NF-KB. Trends in Neurosciences. 2005;28(1):37-43.
  • Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, Passalacqua G, Canonica GW. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol. 2006 Aug;97(2):141-8.
  • Pershadsingh HA. Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin Investig Drugs. 2004 Mar;13(3):215-28.
  • Pizza G, Amadori M, Ablashi D, De Vinci C, Viza D. Cell mediated immunity to meet the avian influenza A (H5N1) challenge. Med Hypotheses. 2006;67(3):601-8.
  • Plioplys AV. Intravenous immunoglobulin treatment of children with autism. J Child Neurol. 1998 Feb;13(2):79-82.
  • Stubbs EG, Budden SS, Burger DR, Vandenbark AA. Transfer factor immunotherapy of an autistic child with congenital cytomegalovirus. J Autism Dev Disord. 1980 Dec;10(4):451-8.
  • Rea WJ, Didriksen N, Simon TR, Pan Y, Fenyves EJ, Griffiths B. Effects of toxic exposure to molds and mycotoxins in building-related illnesses. Arch Environ Health. 2003 Jul;58(7):399-405.
  • Rea WJ, Ross GH. Food and chemicals as environmental incitants. Nurse Pract. 1989 Sep;14(9):17-8, 28, 30 passim.
  • Rea WJ, Podell RN, Williams ML, Fenyves E, Sprague DE, Johnson AR. Elimination of oral food challenge reaction by injection of food extracts. A double-blind evaluation. Arch Otolaryngol. 1984 Apr;110(4):248-52.
  • Rios-Vazquez R, Marzoa-Rivas R, Gil-Ortega I, Kaski JC. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. Am J Cardiovasc Drugs. 2006;6(4):231-42.
  • Schmidt S, Moric E, Schmidt M, Sastre M, Feinstein DL, Heneka MT. Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. J Leukoc Biol. 2004 Mar;75(3):478-85.
  • Schneider CK, Melmed RD, Barstow LE, Enriquez FJ, Ranger-Moore J, Ostrem JA. Oral Human Immunoglobulin for Children with Autism and Gastrointestinal Dysfunction: A Prospective, Open-Label Study. J Autism Dev Disord. 2006 Jul 15; [Epub ahead of print].
  • Scifo R, Cioni M, Nicolosi A, Batticane N, Tirolo C, Testa N, Quattropani MC, Morale MC, Gallo F, Marchetti B. Opioid-immune interactions in autism: behavioural and immunological assessment during a double-blind treatment with naltrexone. Ann Ist Super Sanita. 1996;32(3):351-9.
  • Sicherer SH, Leung DY. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects. J Allergy Clin Immunol. 2006 Jul;118(1):170-7.
  • Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med. 2006 Jun;12(6):688-92.
  • Storer PD, Xu J, Chavis J, Drew PD. Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J Neuroimmunol. 2005 Apr;161(1-2):113-22.
  • Swedo SE, Leonard HL, Garvey M, Mittleman B, Allen AJ, Perlmutter S, Lougee L, Dow S, Zamkoff J, Dubbert BK. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry. 1998 Feb;155(2):264-71.
  • Swedo SE, Leonard HL, Rapoport JL. The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) subgroup: separating fact from fiction. Pediatrics. 2004 Apr;113(4):907-11.
  • Swedo SE, Grant PJ. Annotation: PANDAS: a model for human autoimmune disease. J Child Psychol Psychiatry. 2005 Mar;46(3):227-34.
  • Tordjman S, Ferrari P, Sulmont V, Duyme M, Roubertoux P. Androgenic activity in autism. Am J Psychiatry. 1997 Nov;154(11):1626-7.
  • Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005 Jan;57(1):67-81.
  • Walker SJ, Hepner K, Segal J, Krigsman A. Persistent ileal measles virus in a large cohort of regressive autistic children with ileocolitis and lymphonodular hyperplasia: revisitation of an earlier study. IMFAR.
  • Weiner JM. Allergen injection immunotherapy. Med J Aust. 2006 Aug 21;185(4):234.
  • Werner-Klein M, Kalkbrenner F, Erb KJ. Sublingual immunotherapy of allergic diseases. Expert Opin Drug Deliv. 2006 Sep;3(5):599-612.
  • Youseff S, Steinman L. At once harmful and beneficial: the dual properties of NFKB. Nature Immunology. 2006; 7(9):901-902
  • Zimecki M, Artym J. Therapeutic properties of proteins and peptides from colostrum and milk. Postepy Hig Med Dosw. 2005;59:309-23.

Back to Top

Treating the Brain

  • Abidia A, Laden G, Kuhan G, Johnson BF, Wilkinson AR, Renwick PM, Masson EA, McCollum PT. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial. Eur J Vasc Endovasc Surg. 2003 Jun;25(6):513-8.
  • Ashkenazi A, Levin S, Krasilowsky D. Gluten and autism. Lancet. 1980 Jan 19;1(8160):157.
  • Bolman WM, Richmond JA. A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder. J Autism Dev Disord. 1999 Jun;29(3):191-4.
  • Bruni O, Ferri R, Miano S, Verrillo E. L -5-Hydroxytryptophan treatment of sleep terrors in children. Eur J Pediatr. 2004 Jul;163(7):402-7.
  • Bubenik GA, Blask DE, Brown GM, Maestroni GJM, Pang SF, Reiter RJ, Viswanathan M, Zisapel N. Propsects of the clinical utilization of melatonin. Biological Signals and Receptors. 1998;7:195-219.
  • Buchman AL, Fife C, Torres C, Smith L, Aristizibal J. Hyperbaric oxygen therapy for severe ulcerative colitis. J Clin Gastroenterol. 2001 Oct;33(4):337-9.
  • Chez MG, Buchanan CP, Aimonovitch MC, Becker M, Schaefer K, Black C, Komen J. Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol. 2002 Nov;17(11):833-7.
  • Christison GW, Ivany K. Elimination diets in autism spectrum disorders: any wheat amidst the chaff? J Dev Behav Pediatr. 2006 Apr;27(2 Suppl):S162-71.
  • Connor DF, Fletcher KE, Swanson JM.A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999 Dec;38(12):1551-9.
  • Dekleva M, Neskovic A, Vlahovic A, Putnikovic B, Beleslin B, Ostojic M. Adjunctive effect of hyperbaric oxygen treatment after thrombolysis on left ventricular function in patients with acute myocardial infarction. Am Heart J. 2004 Oct;148(4):E14.
  • Dennog C, Gedik C, Wood S, Speit G. Analysis of oxidative DNA damage and HPRT mutations in humans after hyperbaric oxygen treatment. Mutat Res. 1999 Dec 17;431(2):351-9.
  • Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl). 2006 Oct 3.
  • Fischer BH, Marks M, Reich T. Hyperbaric-oxygen treatment of multiple sclerosis. A randomized, placebo-controlled, double-blind study. N Engl J Med. 1983 Jan 27;308(4):181-6.
  • Giannotti F, Cortesi F, Cerquiglini A, Bernabei P. An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord. 2006 Aug;36(6):741-52.
  • Helms AK, Whelan HT, Torbey MT. Hyperbaric oxygen therapy of cerebral ischemia. Cerebrovasc Dis. 2005;20(6):417-26.
  • Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L, Anagnostou E, Wasserman S. Oxytocin Increases Retention of Social Cognition in Autism. Biol Psychiatry. 2006 Aug 10; [Epub ahead of print].
  • Ishizaki A, Sugama M, Takeuchi N. Usefulness of melatonin for developmental sleep and emotional/behavior disorders—studies of melatonin trial on 50 patients with developmental disorders. No To Hattatsu. 1999 Sep;31(5):428-37.
  • Joiner, JT (Ed.). The Proceedings of the 2nd International Symposium on Hyperbaric Oxygenation for Cerebral Palsy and the Brain-Injured Child. Flagstaff, AZ: Best Publishing Company. (2002).
  • Keithahn C, Lerchl A. 5-hydroxytryptophan is a more potent in vitro hydroxyl radical scavenger than melatonin or vitamin C. J Pineal Res. 2005 Jan;38(1):62-6.
  • Kern JK, Miller VS, Cauller PL, Kendall PR, Mehta PJ, Dodd M. Effectiveness of N,N-dimethylglycine in autism and pervasive developmental disorder. J Child Neurol. 2001 Mar;16(3):169-73.
  • Kessler L, Bilbault P, Ortega F, Grasso C, Passemard R, Stephan D, Pinget M, Schneider F. Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care. 2003 Aug;26(8):2378-82.
  • Kidd PM. Autism, an extreme challenge to integrative medicine. Part 2: medical management. Altern Med Rev. 2002 Dec;7(6):472-99.
  • King BH, Bostic JQ. An update on pharmacologic treatments for autism spectrum disorders. Child Adolesc Psychiatr Clin N Am. 2006 Jan;15(1):161-75.
  • Kiralp MZ, Yildiz S, Vural D, Keskin I, Ay H, Dursun H. Effectiveness of hyperbaric oxygen therapy in the treatment of complex regional pain syndrome. J Int Med Res. 2004 May-Jun;32(3):258-62.
  • Kotler M, Rodriguez C, Sainz RM, Antolin I, Menendez-Pelaez A. Melatonin increases gene expression for antioxidant enzymes in rat brain cortex. J Pineal Res. 1998 Mar;24(2):83-9.
  • Liptak GS. Complementary and alternative therapies for cerebral palsy. Ment Retard Dev Disabil Res Rev. 2005;11(2):156-63.
  • Marois P, Vanasse M. Hyperbaric oxygen therapy and cerebral palsy. Dev Med Child Neurol. 2003 Sep;45(9):646-7.
  • Megson MN. Is autism a G-alpha protein defect reversible with natural vitamin A? Med Hypotheses. 2000 Jun;54(6):979-83.
  • Ohnishi T, Matsuda H, Hashimoto T, Kunihiro T, Nishikawa M, Uema T, Sasaki M. Abnormal regional cerebral blood flow in childhood autism. Brain. 2000 Sep;123 ( Pt 9):1838-44.
  • Pangborn, Jon, and Baker, Sidney M. Autism: Effective Biomedical Treatments (Have We Done Everything We Can For This Child? Individuality In An Epidemic). San Diego: Autism Research Institute, 2005:299-301.
  • Posey DJ, Puntney JI, Sasher TM, Kem DL, McDougle CJ. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol. 2004 Summer;14(2):233-41.
  • Reiter RJ, Tan DX, Burkhardt S. Reactive oxygen and nitrogen species and cellular and organismal decline: amelioration with melatonin. Mech Ageing Dev. 2002 Apr 30;123(8):1007-19.
  • Rimland B. Dimethylglycine, a nontoxic metabolite, and autism. Autism Research Review International. 1990;4(2)3.
  • Rockswold GL, Ford SE, Anderson DC, Bergman TA, Sherman RE. Results of a prospective randomized trial for treatment of severely brain-injured patients with hyperbaric oxygen. J Neurosurg. 1992 Jun;76(6):929-34.
  • Rossignol DA, Rossignol LW. Hyperbaric oxygen therapy may improve symptoms in autistic children. Med Hypotheses. 2006;67(2):216-28. Epub 2006 Mar 22.
  • Ryu YH, Lee JD, Yoon PH, Kim DI, Lee HB, Shin YJ. Perfusion impairments in infantile autism on technetium-99m ethyl cysteinate dimer brain single-photon emission tomography: comparison with findings on magnetic resonance imaging. Eur J Nucl Med. 1999 Mar;26(3):253-9.
  • Sakoda M, Ueno S, Kihara K, Arikawa K, Dogomori H, Nuruki K, Takao S, Aikou T. A potential role of hyperbaric oxygen exposure through intestinal nuclear factor-kappaB. Crit Care Med. 2004 Aug;32(8):1722-9.
  • Stoller KP. Quantification of neurocognitive changes before, during, and after hyperbaric oxygen therapy in a case of fetal alcohol syndrome. Pediatrics. 2005 Oct;116(4):e586-91.
  • Toda Y, Mori K, Hashimoto T, Miyazaki M, Nozaki S, Watanabe Y, Kuroda Y, Kagami S. Administration of secretin for autism alters dopamine metabolism in the central nervous system. Brain Dev. 2006 Mar;28(2):99-103.
  • Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol Ther. 2006 Mar;109(3):325-38.
  • Welch MG, Ludwig RJ, Opler M, Ruggiero DA. Secretin’s role in the cerebellum: a larger biological context and implications for developmental disorders. Cerebellum. 2006;5(1):2-6.
  • Williams KW, Wray JJ, Wheeler DM. Intravenous secretin for autism spectrum disorder. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003495.
  • Yang Z, Nandi J, Wang J, Bosco G, Gregory M, Chung C, Xie Y, Yang X, Camporesi EM. Hyperbaric oxygenation ameliorates indomethacin-induced enteropathy in rats by modulating TNF-alpha and IL-1beta production. Dig Dis Sci. 2006 Aug;51(8):1426-33.
  • Yasar M, Yildiz S, Mas R, Dundar K, Yildirim A, Korkmaz A, Akay C, Kaymakcioglu N, Ozisik T, Sen D. The effect of hyperbaric oxygen treatment on oxidative stress in experimental acute necrotizing pancreatitis. Physiol Res. 2003;52(1):111-6.
  • Yildiz S, Kiralp MZ, Akin A, Keskin I, Ay H, Dursun H, Cimsit M. A new treatment modality for fibromyalgia syndrome: hyperbaric oxygen therapy. J Int Med Res. 2004 May-Jun;32(3):263-7.

Back to Top
 

OUR PRODUCTS

Trusted by Mom’s Everywhere

From foundational guidance to vaccination support, our products are pharmaceutical grade, organic, and scientifically studied to enhance your child’s immune system and neurological system. 

GET FREE ACCESS!

Dr.Ashley Mayer, founder of Dr.Green Mom®, is on a mission to provide you and your family with the tools to live a healthy life, TODAY. You deserve quality heatlhcare information that’s easy to understand, and even easier to implement.

Sign up today to get VIP access to her eBooks, health tips, and
up-to-date vaccine information for FREE!

FREE Guide to
Prepare for Vaccines
7 Secrets to
Prevent Sick Kids
Premium
Newsletter
Yes, sign me up for marketing emails from Dr. Ashley. For more information on how we use your information, check out our Privacy Policy. You can change your mind anytime by unsubscribing.

Order your Vaccine
Strategy Guide Today!
    Cart